Document:

Exhibit 10.12

 

	Certain information in this document, marked by brackets [****], has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K under the Securities Act of 1933, as amended, because it is both (i) not material and (ii) would likely cause competitive harm to the registrant if publicly disclosed.

 

Global Access Commitments Agreement

 

This Global Access Commitments
Agreement (including all appendices, exhibits and attachments hereto, the “Agreement”) is entered into as of September 1,
2021 (“Effective Date”), by and among the Bill & Melinda Gates Foundation, a Washington charitable trust that
is a tax-exempt private foundation (the “Foundation”), Exscientia Limited (registered number 13483814), a private limited
company incorporated in England and Wales (the “Company”) and Exscientia AI Limited, (registered
number SC428761), a private limited company incorporated under the laws of Scotland that is a wholly-owned subsidiary of the Company (“Exscientia”),
in connection with the investment by the Foundation of Thirty-Five Million dollars (US$35,000,000) (the “Foundation Investment”)
in American Depositary Shares of the Company. The Foundation is making the Foundation Investment to induce the Company and Exscientia
to perform the Global Access Commitments set forth herein, and the Company and Exscientia acknowledge and agree that they would not undertake
such Global Access Commitments absent the Foundation Investment. The Foundation Investment will be made in accordance with the Subscription
Agreement dated September 1, 2021 (the “Investment Agreement”), this Agreement, and any additional agreements
executed in connection therewith (collectively, and together with any additional agreements that may be executed in connection with the
Foundation Investment, in each case as amended from time to time in accordance with their terms, the “Investment Documents”).
The Foundation Investment is conditioned upon the execution and delivery of the applicable Investment Documents by the parties thereto
and the Foundation obtaining a written legal opinion from tax counsel that the Foundation Investment will qualify as a program-related
investment under the Code.

 

In consideration of the Foundation
making the Foundation Investment on the terms and conditions stated herein and in the Investment Documents, and for other good and valuable
consideration, the parties hereto hereby irrevocably agree as follows:

 

1.            Definitions.
For the purposes of this Agreement the following terms have the meanings indicated.

 

“Acquisition Transaction” means
(a) the acquisition, directly or indirectly, after the date of this Agreement, by any person or group (within the meaning of Section 13(d)(3) of
the Exchange Act) of beneficial ownership of securities of the Company or Exscientia possessing more than 50% of the total combined voting
power of all outstanding voting securities of the Company or Exscientia, as applicable, (b) a merger, consolidation or other similar
transaction involving the Company or Exscientia, except for a transaction in which the holders of the outstanding voting securities of
the Company or Exscientia, as applicable, immediately prior to such merger, consolidation or other transaction hold, in the aggregate,
securities possessing more than 50% of the total combined voting power of all outstanding voting securities of the surviving entity immediately
after such merger, consolidation or other transaction, or (c) an assignment, sale, transfer or exclusive license of all or substantially
all of the Company’s or Exscientia’s assets, whether by merger, stock transfer, or otherwise.

 

Certain confidential information
contained in this document, marked by [****], has been omitted because it is both (i) not material and (ii) is the type that
the registrant treats as private or confidential.

 

     

     

    

 

“Additional Projects” has
the meaning set forth in Section 3(a)(iv).

 

“Affiliate” means, as to any
person or entity, any person or entity that, directly or indirectly, controls, is controlled by or is under common control with such person
or entity at any time and for so long as that control exists, where “control” (for purposes of this definition of “Affiliate”
only) means having the decision-making authority as to the person or entity and, further, control will be deemed to exist where a person
or entity owns more than 50% of the equity (or that lesser percentage that is the maximum allowed to be owned by a foreign corporation
in a particular jurisdiction) entitled to vote regarding composition of the board of directors or other body entitled to direct the affairs
of the person or entity.

 

“Agreement” has the meaning
set forth in the introductory paragraph.

 

“AI Platform” means
(a) the proprietary coding, software, mathematical or probabilistic models that predict the likelihood of compounds being
active against a specified biological target or having a particular ADMET parameter, automated design algorithms, evolutionary
design algorithms, active learning algorithms, an integrated structural database, and structure-based design programs, in each case
which are controlled by the Company or any of its Affiliates and which comprise the Company’s or any of its Affiliate’s
artificial intelligence-based drug discovery platform; and (b) any enhancement, refinement, modification or improvement to any
technology falling within the scope of (a); but in all events the “AI Platform” excludes the data, information and other
output generated through the use of the foregoing items in (a) and (b) above, including identification of compounds and
associated data and information.

 

“Antiviral Product” means any
product developed by the Company or any of its Affiliates to treat the Target Diseases and Conditions.

 

“Antiviral Program” means collectively
the Initial Antiviral Projects, any Additional Projects, and the Foundation grant Investment ID INV-031996 (GPP COVID-19 CTA: AI-accelerated
discovery of a Mpro inhibitors), including further development, and any and all associated compounds, compound designs, data, documentation,
test results, or other information that is owned or controlled, by the Company or its Affiliates, as further described below.

 

“Background IP” means all Intellectual
Property acquired, licensed, made, conceived or first reduced to practice by or for Exscientia, the Company or any of their respective
Affiliates prior to commencement or independent of the Antiviral Program. For clarity the portions of the Platform Technology made, conceived
or first reduced to practice prior to commencement or independent of the Antiviral Program is included within Exscientia and Company Background
IP.

 

“Bankruptcy Code” means the
United States Bankruptcy Code (11 U.S.C. Section 101 et seq.), as amended from time to time, and any successor statute.

 

“Charitability Default” has
the meaning set forth in Section 5(b).

 

Certain confidential information contained in this document, marked
by [****], has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private
or confidential.

 

     

     

    

 

“Charitable Purpose” has the
meaning set forth in Section 2(a).

 

“Claim” has the meaning set
forth in Section 13.

 

“Code” means the United States
Internal Revenue Code of 1986, as amended.

 

“COGS” means, with respect
to an Antiviral Product, the Company’s and Exscientia’s fully burdened manufacturing and sales costs, which shall include:
(a) all costs incurred in manufacturing such product; (b) all amounts paid to suppliers of any applicable ingredients or materials
with respect to such product, (c) all costs incurred in connection with the storage, testing, shipment (including freight), packaging,
labelling, warehousing or customs clearance for any such product; (d) any insurance costs with respect to such product; (e) all
overhead and employee expenses directly and reasonably incurred by the Company and Exscientia in connection with the manufacturing, marketing
or distribution of any such product in Developing Country markets (including regulatory and licensing costs); and (f) all sales taxes,
duties and tariffs incurred by the Company and Exscientia in the manufacture, distribution and sale of such product in Developing Countries.
In no event shall COGS include costs covered by any Antiviral Program-related funding provided by the Foundation (including the Foundation
Investment), any Foundation-Supported Entity, or other non-dilutive government, multilateral organization, or public sector funding.

 

“Company” has the meaning set
forth in the introductory paragraph.

 

“Developing Countries” means
those countries described as “Developing Countries” on Appendix A.

 

“Dispute” has the meaning set
forth in Section 19.

 

“Effective Date” has the meaning
set forth in the introductory paragraph.

 

“Escrow Agent” has the meaning
set forth in Section 3(i)(iii).

 

“Escrow Agreement” has the
meaning set forth in Section 3(i)(iii).

 

“Escrowed Materials” has the
meaning set forth in Section 3(i)(iii).

 

“Exchange Act” means the United
States Securities Exchange Act of 1934, as amended.

 

“Exercise Event” has the meaning
set forth in Section 3(i)(ii).

 

“Existing Agreements” means
the existing collaboration or license agreements of the Company set forth on Appendix B.

 

“Exscientia” has the meaning
set forth in the introductory paragraph.

 

Certain confidential information contained in
this document, marked by [****], has been omitted because it is both (i) not material and (ii) is the type that the registrant
treats as private or confidential.

 

     

     

    

 

“Fair Market Value” means (a) if
the Foundation Securities are freely tradable, the closing price of the Foundation Securities on the most recent day the Foundation Securities
were traded on the applicable exchange prior to the closing date of the redemption or purchase or (b) if the Foundation Securities
are not freely tradable, the then current fair market value as determined by a mutually agreed upon (such agreement not to be unreasonably
withheld) independent third-party appraiser.

 

“Foundation” has the meaning
set forth in the introductory paragraph.

 

“Foundation Investment” has
the meaning set forth in the introductory paragraph.

 

“Foundation Securities” has
the meaning set forth in Section 5(c).

 

“Foundation-supported Entity”
means an entity selected by the Foundation for participation in a project that receives funding, directly or indirectly, from the Foundation,
collaborates with the Foundation, or both, for the purpose of accomplishing the Foundation’s charitable objectives.

 

“Funded Developments” means
the Intellectual Property made, conceived or first reduced to practice by or on behalf of Exscientia or the Company in connection with
the Antiviral Program. For clarity (a) Antiviral Products and (b) the portions of the Platform Technology made, conceived or
first reduced to practice in connection with the Antiviral Program is included within Funded Developments.

 

“Global Access” means
that (a) knowledge gained using the Foundation’s funding is promptly and broadly disseminated and (b) the products
and technologies developed or supported with the Foundation’s funding will be made available and accessible at an affordable
price to people most in need in Developing Countries.

 

“Global Access Commitments”
has the meaning set forth in Section 3.

 

“Global Health License” has
the meaning set forth in Section 3(i)(i).

 

“Indemnitees” has the meaning
set forth in Section 13.

 

“Initial Antiviral Projects”
has the meaning set forth in Section 3(a)(i).

 

“Intellectual Property” means
all (a) technology and other subject matter, including all: inventions (whether or not patentable), discoveries, machines, equipment,
tangible compositions of matter, devices, articles of manufacture, assays, biological, chemical or physical materials and other similar
materials, processes, formulae, designs, methods, techniques, procedures, concepts, developments, data (including pharmacological, toxicological
and clinical information and test data, and related reports, statistical analyses, expert opinions and the like), information, know-how,
works of authorship, computer applications, software, files, databases, documentation, reports and regulatory submissions, drawings, lists
and other proprietary, non-public or confidential information, documents or materials in any media; and (b) Intellectual Property
Rights.

 

Certain confidential information contained in
this document, marked by [****], has been omitted because it is both (i) not material and (ii) is the type that the registrant
treats as private or confidential.

 

     

     

    

 

“Intellectual Property Rights”
means all rights, privileges and priorities provided under federal, state, foreign and multinational law, including any and all: (a) rights
under any of the following, whether existing now or in the future: (i) a domestic, international or foreign patent, utility model,
design registration, certificate of invention, patent of addition or substitution, or other governmental grant for the protection of inventions
or industrial designs anywhere in the world, including any reissue, renewal, re-examination or extension thereof; and (ii) any application
for any of the foregoing, including any international, provisional, divisional, continuation, continuation-in-part, or continued prosecution
application; (b) copyrights and copyright registrations; (c) trade secrets and other rights in know-how; (d) sui generis
protections for databases and other rights in data as intangible property; and (e) rights in trademarks, logos, service marks and
other indicia of origin, all goodwill associated therewith and all applications and registrations with respect thereto.

 

“Investment Agreement” has
the meaning set forth in the introductory paragraph.

 

“Investment Documents” has
the meaning set forth in the introductory paragraph.

 

“Joint Steering Committee”
has the meaning set forth in Section 3(f)(i).

 

“Minimum Purchase Price” means
the original purchase price per share for the Foundation Securities, as adjusted for any conversion, share dividend, share split, combination
or other similar recapitalization or share capital reorganization.

 

“Outbreak” has the meaning
set forth in Section 3(e)(i).

 

“Platform Technology” means
the Intellectual Property acquired, licensed, made, conceived or first reduced to practice by or on behalf of the Company, Exscientia
or one of their respective Affiliates relating to research, development, clinical, regulatory, manufacturing, commercialization, service
and support, and distribution capabilities in respect of small molecule therapeutics and other products, whether such Intellectual Property
exists as of the Effective Date or is later acquired, licensed, made, conceived or first reduced to practice by the Company, Exscientia
or any of their respective Affiliates.

 

For clarity, the Platform Technology includes
the AI Platform but the Global Health License will not apply to the AI Platform.

 

“Required Quantities” has the
meaning set forth in Section 3(e)(i).

 

“SAR” has the meaning set
forth in Section 3(g)(ii).

 

“Securities Act” means the
Securities Act of 1933, as amended.

 

“Target Diseases and Conditions”
means the diseases and conditions set forth on Appendix C, subject to amendment as set forth on Appendix C.

 

“TPP” has the meaning set forth
in Section 3(a)(iv).

 

Certain confidential information contained in this document, marked
by [****], has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private
or confidential.

 

     

     

    

 

“Use” means to reproduce, modify,
have modified, create and have created derivative works of, distribute, manufacture, use, sell, offer for sale, import and otherwise dispose
of, commercialize and otherwise exploit.

 

“Withdrawal Right” has the
meaning set forth in Section 5(c).

 

2.            Charitable
Purpose; Use of Proceeds.

 

(a)            Charitable
Purpose. The Foundation is making the Foundation Investment as a “program-related investment” within the meaning of Section 4944(c) of
the Code. The Foundation’s primary purpose in making the Foundation Investment is to further significantly the accomplishment of
the Foundation’s charitable purposes, including the relief of the poor, distressed and underprivileged, the advancement of science,
and the promotion of health by accelerating the development of lifesaving and low-cost drugs, vaccines, therapeutics and diagnostics to
reduce the burden of disease in Developing Countries in furtherance of its mission to help all people lead healthy, productive lives (collectively,
the “Charitable Purpose”). In furtherance of the Charitable Purpose, the Foundation requires that the innovations,
products and information developed with its funding be created and managed to ensure Global Access can be achieved. In furtherance of
the Charitable Purpose, the Foundation Investment in the Company will secure the Global Access Commitments set forth below.

 

(b)            Use
of Proceeds. The Company through its subsidiary, Exscientia, will use the proceeds from the Foundation Investment solely in furtherance
of the Charitable Purpose to conduct the Initial Antiviral Projects as described below. The proceeds from the Foundation Investment will
not be required to be segregated in a separate account nor required to be used for dedicated employees or facilities.

 

3.            Global
Access Commitments.

 

As a condition to the Foundation
making the Foundation Investment and to ensure satisfaction of the Charitable Purpose, the Company and Exscientia agree to the following
(collectively “Global Access Commitments”):

 

(a)            Conduct
of Antiviral Program; Initial Antiviral Projects.

 

(i)            Exscientia
will diligently establish and conduct the Antiviral Program, beginning with the Initial Antiviral Projects. The “Initial Antiviral
Projects” means a four (4) year, $70 million program to apply the Platform Technology to research, discover, and develop
small molecule anti-infective therapeutics for future pandemic preparedness, with a specific focus on developing therapeutics that can
be applied against multiple species of coronaviridae, influenza, and paramyxoviridae. Exscientia will dedicate a team of at least [****],
to conduct the Initial Antiviral Projects and will conduct the Initial Antiviral Projects in accordance with the Scope of Work in Appendix
D.

 

(ii)           The
Company, through its subsidiary, Exscientia, will use the proceeds from the Foundation Investment solely to fund the Initial Antiviral
Projects and in addition will provide $35 million in matching contributions, through both in-kind support and funding for third-party
activities. Exscientia will provide quarterly reports that specify the nature and amounts of the in-kind support and funding for third-party
activities provided by Exscientia with respect to the Initial Antiviral Projects, and will provide such additional information as the
Foundation may reasonably request to confirm these amounts. For clarity, the Initial Antiviral Projects will not include funding from
prior grants of the Foundation or require additional funding from the Foundation other than the Foundation Investment to support the Company’s
or Exscientia’s internal or third-party activities.

 

Certain confidential information
contained in this document, marked by [****], has been omitted because it is both (i) not material and (ii) is the type that
the registrant treats as private or confidential.

 

     

     

    

 

(iii)          The
Company and Exscientia will be free to share the compounds and data from the Antiviral Program with other internal programs
conducted by the Company or Exscientia or any of their respective Affiliates, provided that neither the Company nor Exscientia will
grant to a third-party any license or other rights or enter into any arrangements or agreements or otherwise take any actions that
would limit or restrict the Foundation’s right to continue with further development or any other Global Access Commitments,
including with respect to the Funded Developments and Antiviral Products.

 

(iv)          In
addition to the Initial Antiviral Projects, if requested by the Foundation, Exscientia will utilize the Platform Technology and data collected
in the Antiviral Program to diligently conduct up to two “Additional Projects” proposed at the discretion of the Foundation
or a Foundation-supported Entity. Each Additional Project will be conducted by the Company and Exscientia utilizing the Platform Technology
to research and develop a drug or other product with respect to any Target Disease and Condition selected by the Foundation. If the Foundation
requests Exscientia to conduct an Additional Project, the Company and Exscientia will negotiate in good faith with the Foundation or a
Foundation-Supported Entity designated by the Foundation to reach agreement upon a scope of work and Target Product Profile (“TPP”)
for the Additional Project. Each Additional Project will be funded and conducted pursuant to the Foundation’s standard funding terms
and processes, which would include a proposal prepared in good faith by the Company and Exscientia describing the relevant work to be
conducted by the Company and Exscientia and other related documents acceptable to the Foundation.

 

(v)          As
part of the Antiviral Program, prior to the initiation of phase 2 clinical studies of any Antiviral Product, Exscientia will develop a
plan in consultation with the Foundation to minimize delays in availability of Antiviral Products in Developing Countries versus non-Developing
Countries. Such a plan should outline activities to facilitate World Health Organization Pre-Qualification, emergency use authorization(s),
or other relevant regulatory approvals for Developing Countries, and manufacturing activities such as stockpiling or identification and
qualification of potential manufacturing partners with cGMP standards verified by a competent stringent regulatory authority.1

 

(vi)         After
Exscientia has completed the initial scope of work for the Initial Antiviral Projects, the Foundation will have the right, at its sole
discretion, to provide grant funding (directly or through a Foundation-supported Entity) to advance the Antiviral Products through development,
manufacturing, commercialization and distribution of a final product in accordance with the applicable TPP, in accordance with Section 3(b) below,
provided that any such additional grant funding will be in the Foundation’s discretion and subject to execution of grant documents
for such projects in accordance with the Foundation’s standard grant making process.

 

 

1
https://www.who.int/initiatives/who-listed-authority-reg-authorities/SRAs

 

Certain confidential information contained in this document, marked
by [****], has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private
or confidential.

 

     

     

    

 

(vii)         Exscientia
will use the same level of diligence, efforts, resources, time, and expediency in conducting the Antiviral Program and Outbreak Response
as Exscientia uses with respect to the research and development, manufacturing, regulatory approval and commercialization of any other
Exscientia products at a similar stage in development, including Exscientia’s lead commercial products intended for markets other
than in Developing Countries, including using the same level of diligence with respect to the identification and training of manufacturing
partners, technology transfer to partners in a way that minimizes COGS, and delivery in Developing Countries that Exscientia uses in markets
other than Developing Countries.

 

(b)            Further
Development.

 

(i)            Following
completion of the initial scope of work for the Initial Antivirals Projects or an Additional Project, if the Foundation requests the Company
and/or Exscientia to conduct further development, modifications, or clinical trials with respect to the Antiviral Products, the Company
and Exscientia will negotiate in good faith with the Foundation or a Foundation-Supported Entity designated by the Foundation to reach
agreement upon a project plan, which may include work to be undertaken, responsibilities, participation by other parties, timelines and
milestones, project management, contributions in-kind and funding requirements, a commercialization plan, and any additional Global Access
commitments. The specific level of funding responsibilities for the additional work will be mutually agreed in good faith in a written
agreement between the parties. In no event will the Foundation be responsible for any amount of such funding that would constitute a taxable
expenditure under Treasury Regulation 53.4945-6(a)-(b). Any additional work may be divided into milestones or phases. The Foundation will
have the right, at its sole and absolute discretion, to continue providing funding (directly or through a Foundation-supported Entity)
to advance the Antiviral Products through to product launch of a final product for the purpose of enabling Global Access. For the avoidance
of doubt, if the Foundation elects to proceed with further development it will provide additional funding as described herein.

 

(ii)           If
the Company or Exscientia elects to conduct further development of an Antiviral Product without additional funding from the Foundation,
the Company and/or Exscientia, as applicable, will not grant to a third-party any rights or enter into any arrangements or agreements
or otherwise take any actions that would limit or restrict the Foundation’s right to continue with further development or the Global
Access Commitments, including with respect to the Funded Developments and Antiviral Products.

 

(c)            Intellectual
Property Rights. The Company and Exscientia represent and covenant that the Company and/or Exscientia has and will continue to have
all necessary rights to the Platform Technology, Funded Developments and Background IP (including all Intellectual Property Rights and
other right in data, confidential information, know-how, and other Intellectual Property) needed to perform the Global Access Commitments
and grant the licenses hereunder.

 

(d)            Pricing
and Volume Commitments. The Company and Exscientia agree that they will make all Antiviral Products available in Developing Countries
(i) at a price [****] and (ii) in quantities meeting or exceeding those set forth in the applicable statement of work (or other
applicable Global Access agreements between the Foundation and the Company and/or Exscientia). It is understood that no party will be
expected to undertake sales of an Antiviral Product at a loss.

 

Certain confidential information contained in this document, marked
by [****], has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private
or confidential.

 

     

     

    

 

(e)            Outbreak
Response.

 

(i)            In
the event of an emerging or declared public health crisis either in Developing Countries as determined by a relevant governmental entity,
multilateral organization or by mutual agreement of the parties (an “Outbreak”), if requested by the Foundation, the
Company and Exscientia will agree to make available in Developing Countries relevant Antiviral Products, through their own manufacturing
or existing out-licensing arrangements with other manufacturers, in sufficient quantities to meet reasonably expected demand in Developing
Countries (“Required Quantities”).

 

(ii)           If
the Company and Exscientia cannot manufacture the Required Quantities plus the volumes reasonably expected outside Developing Countries
through their own manufacturing or existing out-licensing arrangements with other manufacturers, then the Company and Exscientia will
work with the Foundation or a Foundation-Supported Entity designated by the Foundation to develop a manufacturing and/or licensing plan
to produce the Required Quantities. The specific level of funding responsibilities for the manufacturing and/or licensing plan will be
decided as mutually agreed in good faith in a written agreement between the parties.

 

(iii)          It
is understood that in the event of an Outbreak, the pricing and volume commitments in Section 3(d) will apply. It is
further understood that in the event of an Outbreak, available capacity for the relevant Antiviral Product will be allocated to
Developing Countries (in aggregate) at a percentage of available capacity that is [****],
for each quarter of production for the duration of the Outbreak.

 

(iv)          If
the Antiviral Product does not meet the COGS criteria outlined in the applicable TPP, the Company will make a good faith effort to consider
donations of the Antiviral Product to Developing Countries.

 

(f)            Joint
Steering Committee.

 

(i)            The
Company and the Foundation will each designate [****] individuals who are subject matter experts to be part of a joint steering committee
(the “Joint Steering Committee”) that will provide a forum to review and discuss the overall scientific strategy, progress
toward goals and changes to the scope of work, based on agreed upon criteria of each project in the Antiviral Program. At the start of
the Initial Antiviral Projects, the Company will designate [****] as its Joint Steering Committee representatives. Additional non-voting
representatives may attend based on specific agenda topics.

 

(ii)           The
Joint Steering Committee will review the Company’s and Exscientia’s data, portfolio progress, and recommendations and the
following decisions will be subject to the Joint Steering Committee’s authorization: (1) criteria for target prioritization,
(2) prioritization of targets, (3) selection of initial compounds for each viral family, (4) criteria for hit selection,
(5) criteria for selection of CROs and network assay partners, (6) selection of targets and whole-cell assays for antiviral
efficacy evaluation, (7) screening strategy and assay specifications, (8) prioritization of final hits, (9) criteria for
lead selection, (10) preclinical models, (11) selection of final leads, (12) project transitions, and (13) development, partnering,
and Intellectual Property strategy and agreements.

 

Certain confidential information contained in this document, marked
by [****], has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private
or confidential.

 

     

     

    

 

(iii)          The
Company and Exscientia will manage the pipeline of hits and leads such that there is an appropriate balance of projects and resources
to deliver [****] lead candidates [****] and will prioritize leads based on their ability to meet the TPP criteria, including activity
against multiple species within virus families. The pipeline and leads will be reviewed by the Joint Steering Committee and must be acceptable
to the Joint Steering Committee (such acceptance not to be unreasonably withheld).

 

(iv)          The
Joint Steering Committee will meet at least once each calendar quarter via teleconference or videoconference and at least once annually
in-person, if feasible, for the duration necessary to conclude the Initial Antiviral Projects, Additional Projects, and corresponding
further development of related Antiviral Products. With the agreement of both parties and subject to the execution of appropriate confidentiality
agreements, third parties may be invited from time to time to participate in certain Joint Steering Committee discussions. Decisions made
at the Joint Steering Committee must be approved by a majority of the representatives of the Foundation and a majority of the representatives
of the Company. If the members of the Joint Steering Committee from both parties cannot reach mutual agreement on a decision that this
Agreement specifies shall be made by the Joint Steering Committee, then such matter will be resolved in accordance with the dispute resolution
procedure set forth in Section 19.

  

(g)            Publication;
Access to Data and Information. The Company and Exscientia will (in addition to the publication requirements of any other agreements
with the Foundation):

 

(i)            publish
the results and information developed in connection with the Antiviral Program within a reasonable period of time after such information
or results are obtained, subject to reasonable delays or limitations on content of such publications that are necessary to protect Intellectual
Property Rights covering the Platform Technology itself. Subject to the preceding sentence, all publications must be made in accordance
with “open access” terms and conditions consistent with the Foundation’s Open Access Policy (available at: http://www.gatesfoundation.org/How-We-Work/General-Information/Open-Access-Policy),
which may be modified from time to time;

 

(ii)            promptly
provide to the Foundation access to all data, results, and information regarding the Antiviral Program (such data and information will
include, but not be limited to: disease and target KnowledgeGraphs, HotSpot target assessment data, structural domains, “stage 2”
structure-activity-relationship (“SAR”) data, three-dimensional structural models, lists of proposed compounds proposed
for synthesis, SAR data for all synthesized compounds (including chemical structure, biological assay data on potency, cell activity,
physical properties, absorption, distribution, metabolism, and excretion and pharmacokinetic data), and MERIT data. Such data, results
and information will be updated quarterly and maintained in a database/repository that the Foundation can fully access;

 

Certain confidential information
contained in this document, marked by [****], has been omitted because it is both (i) not material and (ii) is the type that
the registrant treats as private or confidential.

 

     

     

    

 

(iii)          promptly
provide to the Foundation rights to share such data and information regarding the Antiviral Program, and the reasonably contemplated use
of the Platform Technology for the Antiviral Program, subject to the reasonable need to protect confidential information and to avoid
untimely public disclosures that may bar access to patent protection or public disclosures that may undermine trade secret protection;
and

 

(iv)          make
a good faith effort to negotiate and agree to a Confidential Disclosure Agreement and share data and information regarding the Antiviral
Program with the to-be-established Pandemics Antiviral Discovery partnership.

 

(h)            No
Inconsistent Rights. Subject to the Existing Agreements, neither the Company nor Exscientia will grant to a third-party any rights
or enter into any arrangements or agreements that would limit or restrict the Foundation’s ability to exercise its rights or the
Company’s or Exscientia’s ability to perform its obligations under this Agreement (including the licenses granted in this
Agreement). The Foundation will not be required to take any action or enter into any arrangement or agreement that would limit or restrict
the Foundation’s ability to exercise its rights under this Agreement.

 

(i)            Global
Health License.

 

(i)            Global
Health License. Each of the Company, Exscientia and their respective Affiliates hereby grants the Foundation and/or
Foundation-supported Entities (at the Foundation’s option and election) a worldwide, exclusive (except as to Company and
Exscientia, as well as with respect to Background IP, for which this license shall be non-exclusive), non-terminable, irrevocable,
perpetual, royalty-free, fully paid up license (with the right to grant and authorize sublicenses) under all Intellectual Property
Rights (other than any Intellectual Property Rights existing in, or which come into existence in, the AI Platform) owned, controlled
or in-licensed by the Company, Exscientia or any of their respective Affiliates to Use the Funded Developments and Background IP for
the purpose of researching, developing, manufacturing, using, selling, offering for sale, distributing, importing, and otherwise
disposing of, commercializing and otherwise exploiting Antiviral Products for the purpose of benefiting people in Developing
Countries (“Global Health License”). The Global Health License is a presently granted license. If an Exercise
Event as described in Section 3(i)(ii) below occurs, all rights and licenses granted under or pursuant to this Agreement
by the Company, Exscientia or any of their respective Affiliates are, and shall be deemed to be, for purposes of
Section 365(n) of the Bankruptcy Code and any similar law or regulation in any other country, licenses of rights to
 "intellectual property" as such term is defined in Section 101(35A) of the Bankruptcy Code. The parties agree that
all Intellectual Property Rights licensed hereunder are part of the "intellectual property" as defined under
Section 101(35A) of the Bankruptcy Code subject to the protections afforded the non-terminating party under
Section 365(n) of the Bankruptcy Code, and any similar law or regulation in any other country. For clarity, the Global
Health License does not grant the Foundation a license or any other right to Use the AI Platform. The Company and Exscientia
represent and warrant that the Funded Developments do not and will not embody any Intellectual Property Rights that are embodied in
the AI Platform and no such Intellectual Property Rights are reasonably required for the Use of the Funded Developments. If
third party Intellectual Property is included within the rights granted under this Section 3(i), the Company shall be
responsible for any royalties or other consideration owed with respect to the Use thereof in exercise of the foregoing license.

 

Certain confidential information contained in
this document, marked by [****], has been omitted because it is both (i) not material and (ii) is the type that the registrant
treats as private or confidential.

 

     

     

    

 

(ii)           Exercise
Events. The Foundation will not exercise its rights under the Global Health License (including its sublicensing rights) unless at
least one of the following occurs (each, an “Exercise Event”):

 

(A)            a
Charitability Default; or

 

(B)            the
Company or Exscientia (including any successors or assigns or the Affiliates of the Company or Exscientia, or their respective successors
or assigns) (i) institutes any bankruptcy, insolvency, appointment of a receiver and/or trustee or reorganization (in either case
for the release of financially distressed debtors), general assignment for the benefit of creditors, winding-up, dissolution, liquidation
or similar proceeding relating to it under the laws of any jurisdiction or any such proceeding is instituted against the Company or Exscientia
which remains undismissed or unstayed for a period of [****] or (ii) ceases to conduct business in the ordinary course or is determined
to no longer be a going concern.

 

If either the Foundation,
the Company or Exscientia becomes aware of an Exercise Event, it will promptly notify the other parties in writing of the occurrence of
such Exercise Event; provided that failure by the Foundation to provide such notice will not affect the Foundation’s rights hereunder.

 

(iii)          Escrow.
Within [****] after the Effective Date, the Company and Exscientia shall (A) negotiate with a third party escrow agent mutually
acceptable to the Company and the Foundation (the “Escrow Agent”) an escrow agreement by and among such Escrow
Agent, the Company, Exscientia and the Foundation (the “Escrow Agreement”) and (B) deposit with the Escrow
Agent, pursuant to such Escrow Agreement, the Intellectual Property covered by the Global Health License, including the data,
results, and information referenced in Section 3(g)(ii) and samples of synthesized compounds (collectively, the
 “Escrowed Materials”). The release conditions to be set forth in the Escrow Agreement will be the same as an
Exercise Event. The Company and Exscientia shall update the Escrowed Materials quarterly. The Escrow Agreement will include a
process to enable verification of the Escrowed Materials and updates thereto by the Foundation. The Foundation will have the right
to obtain release of any of the Escrowed Materials from the Escrow Agent at any time following a Charitability Default to the extent
necessary to enable the Foundation to exercise the Global Health License.

 

(j)             Cooperation;
Technology Transfer. In connection with the exercise of the Global Health License, each of the Company and Exscientia will take further
actions, including Intellectual Property transfer (subject to appropriate confidentiality obligations), as would be commercially reasonable
industry practice at the time with respect to providing a biotechnology license to a third party, to accommodate that the Foundation,
the Foundation’s sublicensees, and/or the relevant Foundation-supported Entity can effectively exercise the Global Health License
and use the related technology and manufacture the relevant products if an Exercise Event occurs (including the right to reference regulatory
filings related to the applicable Antiviral Products).

 

(k)            Duration
of Global Access Commitments. The Global Access Commitments will be ongoing and will continue for as long as the Foundation exists.

 

Certain confidential information contained in this document, marked
by [****], has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private
or confidential.

 

     

     

    

 

4.            Survival
of Global Access Commitments.

 

In the event of (i) an
Acquisition Transaction, or (ii) the sale, exclusive license, or other transfer of the Platform Technology or the Funded Developments,
the Global Access Commitments will survive and be assumed in full by the purchaser, transferee, licensee, or acquirer and the Company
and Exscientia will take all action necessary to ensure such assumption. Prior to signing the definitive agreement with respect to a transaction
described in the previous sentence, the Company and Exscientia will allow the Foundation to review the provisions of the written agreement
with such third-party that relate to the assumption of the Global Access Commitments to confirm that the Global Access Commitments will
survive and be assumed by the third-party and will continue to be directly enforceable by the Foundation. For clarity, notwithstanding
anything to the contrary in this Agreement, the Foundation’s rights hereunder that exist on the date of the Acquisition Transaction
or sale, exclusive license, or other transfer of the Platform Technology or the Funded Developments will not be terminated by any such
transaction.

 

In
addition, at the earlier to occur of (a) the agreement by the Company or Exscientia with a third party on the key terms of an Acquisition
Transaction or the sale, exclusive license, or other transfer of the Platform Technology or the Funded Developments or (b) [****]
prior to the closing of an Acquisition Transaction the sale,
exclusive license, or other transfer of the Platform Technology or the Funded Developments, the Company will provide the Foundation with
written notice of the proposed Acquisition Transaction or sale, license or other transfer.

 

5.            Withdrawal
Right.

 

(a)            The
Withdrawal Right described and defined in this Section 5 will be triggered only as a result of a Charitability Default.

 

(b)            A
 “Charitability Default” means that the Company or Exscientia (i) is in material breach of any of the Global Access
Commitments, including the failure to conduct the Antiviral Program as described herein, other than for reasons of technical or scientific
failure not within the control of the Company or Exscientia and not known to the Company or Exscientia at or before closing of the Foundation
Investment, (ii) fails to comply with the restrictions in Sections 2 and 8 of this Agreement on the use of proceeds from the Foundation
Investment, or (iii) fails to comply with the other related U.S. legal obligations set forth in this Agreement, including the requirements
set forth in Sections 6, 10, and 11. Each party agrees to promptly notify the other party in writing if it becomes aware of a Charitability
Default and the Company and Exscientia will thereafter promptly provide to the Foundation a proposed strategy to remedy the Charitability
Default. Notwithstanding the foregoing, the Foundation will not lose any rights or remedies solely as a result of a failure to notify
the Company or Exscientia after it becomes aware of a Charitability Default.

 

(c)            If
the Company or Exscientia fails to cure the Charitability Default within [****] of the occurrence thereof, and if the Foundation holds
any securities of the Company issued in connection with the Foundation Investment, including securities issued in respect of or upon conversion
or exercise of such securities (collectively, the “Foundation Securities”), the Company will have the obligation, if
requested by the Foundation, to (i) repurchase all of the Foundation Securities at a price per share equal to the greater of the
Minimum Purchase Price or the Fair Market Value, or (ii) locate a third-party that will purchase the Foundation Securities at price
per share equal to the greater of the Minimum Purchase Price or the Fair Market Value ((i) and (ii), the “Withdrawal Right”).
If the Company is unable to repurchase all of the Foundation Securities, and no third party purchases the Foundation Securities, then
the Company will use its best efforts to effect the Withdrawal Right, consistent with the Code and applicable law, as soon as practicable.

 

Certain confidential information contained in this document, marked
by [****], has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private
or confidential.

 

     

     

    

 

 

(d)            If
at the time of a Charitability Default the Foundation Securities consist of a class of securities of the Company that (i) is registered
under section 12 (or any successor provision) of the Securities Exchange Act of 1934, as amended, (ii) is not subject to restrictions
from trading under the Securities Act or state securities laws and (iii) is listed on a U.S. national securities exchange and the
Company is current in filing its financial reports and other required filings with the Securities and Exchange Commission, then the Company
may elect to satisfy the Withdrawal Right by registering the resale of the Foundation Securities on an effective registration statement
filed under the Securities Act and keeping the registration statement continuously effective under the Securities Act until the earlier
of (x) the date all of the Foundation Securities have been sold and (y) the date that is [****] following the effective date
of the registration statement; provided that the Company shall not be obligated to register the resale of the Foundation Securities if
the Foundation can sell the Foundation Securities to the public under Rule 144 of the Securities Act without volume limitations.
If the Company elects to satisfy the Withdrawal Right pursuant to this provision and the Foundation receives less than the Minimum Purchase
Price, then the Company will pay the Foundation as soon as practicable the difference between the amount received by the Foundation as
a result of the sale of the Foundation Securities on the securities exchange and the amount of the Minimum Purchase Price. The Company
shall pay all registration and other fees and expenses incident to the performance of or compliance with this provision, including the
legal fees of a single counsel to the Foundation.

 

(e)            During
the period when the Company is unable to exercise its obligation to repurchase or find a purchaser of the Foundation Securities, the
Company will not pay dividends on any of its shares, repurchase the shares of any other shareholder of the Company (excluding repurchases
of shares from former employees, officers, directors, consultants or other persons who performed services for the Company or any subsidiary
in connection with the cessation of such employment or service at the lower of the original purchase price or the then-current fair market
value thereof) or otherwise make any other distribution to any other shareholder of the Company (other than ordinary shares or share
options issued to employees or directors of, or consultants or advisors to, the Company or any of its subsidiaries pursuant to a plan,
agreement or arrangement approved by the Board of Directors of the Company).

 

(f)            Notwithstanding
any exercise of the Withdrawal Right by the Foundation, the Foundation’s rights under the Global Access Commitments will survive. 

 

Certain confidential information contained in this document, marked
by [****], has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private
or confidential.

 

     

     

    

 

6.            Required
Reporting; Audit Rights.

  

(a)            In
addition to reports required to be delivered to the Foundation under the Investment Documents and Section 3(g) above, the Company
and Exscientia will furnish, or cause to be furnished, to the Foundation the following reports and certifications: 

 

(i)            within
[****] after the end of each of the Company’s and Exscientia’s fiscal years during which the Foundation owns any securities
in the Company, a certificate from the Company and Exscientia signed by an officer of the Company and Exscientia and substantially in
the form attached to this Agreement as Appendix E, certifying that the requirements of the Foundation Investment set forth in
this Agreement were met during the immediately preceding fiscal year, describing the use of the proceeds of the Foundation Investment,
the in-kind support and funding for third-party activities provided by the Company and Exscientia with respect to the Initial Antiviral
Projects and evaluating the Company’s and Exscientia’s progress toward achieving the Global Access Commitments; 

 

(ii)            within
[****] after the end of the Company’s and Exscientia’s fiscal year during which the Foundation ceases to own any securities
in the Company, a certificate from the Company and Exscientia signed by an officer of the Company and Exscientia and substantially in
the form attached to this Agreement as Appendix F, certifying that the requirements of the Foundation Investment set forth in
this Agreement were met during the term of the Foundation Investment, describing the use of the proceeds of the Foundation Investment,
the in-kind support and funding for third-party activities provided by the Company and Exscientia with respect to the Initial Antiviral
Projects and evaluating the Company’s and Exscientia’s progress toward achieving the Global Access Commitments; 

 

(iii)            any
other information respecting the operations, activities and financial condition of the Company and Exscientia as the Foundation may from
time to time reasonably request to discharge any expenditure responsibility, within the meaning of Sections 4945(d)(4) and 4945(h) of
the Code, of the Foundation with respect to the Foundation Investment, and to otherwise monitor the charitable benefits intended to be
served by the Foundation Investment. The Foundation will reimburse the Company and Exscientia for any reasonable third-party expenses
incurred by the Company or Exscientia in order to prepare any information they are required to prepare solely as a result of this Section 6(a)(iii);
and

 

(iv)            full
and complete financial reports of the type ordinarily required by commercial investors under similar circumstances to the extent required
pursuant to Treasury Regulation 53.4945-5(b)(4). 

 

(b)            At
the Foundation’s reasonable request, the Company and Exscientia will provide the Foundation with a summary of scientific data and
progress to date on the Antiviral Program and any Platform Technology related to the foregoing, and the considerations made by the Company
and Exscientia with respect to accessibility, affordability and cost-effectiveness of the applicable Antiviral Products for the benefit
of people in Developing Countries, in addition to the information that may be required under any grant agreements or other funding agreements. 

 

(c)            Without
limiting the foregoing, at the Foundation’s request, the Company and Exscientia will permit the Foundation or its representatives
to inspect (at a reasonable time and location) the scientific records of the Company and Exscientia relating to the Antiviral Program
and any Antiviral Products with due regard to the reasonable need to protect trade secrets covering the Platform Technology. 

 

Certain confidential information contained in this document, marked
by [****], has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private
or confidential.

 

     

     

    

 

(d)            The
Company and Exscientia shall maintain books and records adequate to provide such information as is necessary to document the use of the
Foundation Investment in compliance with Treasury Regulations section 53.4945-5(b)(4), as amended from time to time and the in-kind support
and funding for third-party activities provided by the Company and Exscientia with respect to the Initial Antiviral Projects. The Company
and Exscientia will retain such books and records for [****] after the Foundation ceases to hold Company securities and will make such
books and records available to the Foundation at reasonable times to enable the Foundation to monitor and evaluate how the Foundation’s
funds have been used. 

 

(e)            The
Company and Exscientia will permit employees or agents of the Foundation at any reasonable time and upon reasonable prior notice,
during normal business hours, to examine or audit the Company’s and Exscientia’s books and accounts of record, in each
case at the Foundation’s expense to audit the Company’s and Exscientia’s compliance with the use of the Foundation
Investment and the Global Access Commitments; provided that the Foundation will not conduct any such audit more than [****]. If the
Company or Exscientia maintains any records (including computer-generated records and computer software programs for the generation
of such records) in the possession of a third party, then in connection with any audit described in the preceding sentence, the
Company and Exscientia, upon request of the Foundation, will notify such party to permit the Foundation access to such records in
connection with such audit, all at the Foundation’s expense.

 

7.            Assignment.

 

Notwithstanding anything
in this Agreement or any Investment Document to the contrary, the Foundation will have the right to assign this Agreement or transfer
the Foundation Securities to (a) any successor charitable organization of the Foundation from time to time that is a tax-exempt
organization as described in Section 501(c)(3) of the Code, or (b) any tax-exempt organization as described in Section 501(c)(3) of
the Code controlled by one or more trustees of the Foundation, provided that Exscientia has provided its prior written consent (which
it will not unreasonably withhold, condition or delay). The Foundation will notify the Company of any such assignment, including the
identity of the assignee, in a timely manner. For the avoidance of doubt, if the Foundation transfers the Foundation Securities as permitted
by this Section 7, the Foundation may assign to any such transferee all of its rights attached to such Foundation Securities, including
the Withdrawal Right.

 

8.            Prohibited
Uses.

 

Neither the Company nor Exscientia
will expend any proceeds of the Foundation Investment to carry on propaganda or otherwise to attempt to influence legislation, to influence
the outcome of any specific public election or to carry on, directly or indirectly, any voter registration drive, or to participate or
intervene in any political campaign on behalf of or in opposition to any candidate for public office within the meaning of Section 4945(d) of
the Code. The proceeds of the Foundation Investment will not (a) be earmarked to be used for any activity, appearance or communication
associated with the activities described in the foregoing sentence, nor (b) be intended for the direct benefit, and will not benefit,
any person having a personal or private interest in the Foundation, including descendants of the founders of the Foundation, or persons
related to or controlled by, directly or indirectly, such private interests.

 

Certain confidential information contained in this document, marked
by [****], has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private
or confidential.

 

     

     

    

 

For the avoidance of doubt,
the Company will not use the funds received from the Foundation to pay a dividend or redeem shares.

 

9.            Disqualified
Person. 

 

Neither the Company nor (to
the best knowledge of the Company) any stockholder of the Company is a “disqualified person” with respect to the Foundation
(as the term “disqualified person” is defined in Section 4946(a) of the Code). The Foundation does not, and one
or more disqualified persons with respect to the Foundation do not, directly or indirectly, control the Company. 

 

10.            Anti-Terrorism. 

 

Neither the Company nor Exscientia
will use any portion of the Foundation Investment, directly or indirectly, in support of activities (a) prohibited by U.S. laws
related to combatting terrorism; (b) with persons on the List of Specially Designated Nationals (www.treasury.gov/sdn) or entities
owned or controlled by such persons; or (c) in or with countries or territories against which the U.S. maintains comprehensive sanctions
(currently, Cuba, Iran, Syria, North Korea, and the Crimean Region of Ukraine), including paying or reimbursing the expenses of
persons from such countries or territories, unless such activities are fully authorized by the U.S. government under applicable law and
specifically approved by the Foundation in its sole discretion. 

 

11.            Anti-Corruption
and Anti-Bribery. 

 

Neither the Company nor Exscientia
will offer or provide money, gifts, or any other things of value directly or indirectly to anyone in order to improperly influence any
act or decision relating to the Foundation or any activities contemplated by this Agreement, including by assisting any party to secure
an unlawful advantage. Training and information on compliance with these requirements are available at www.learnfoundationlaw.org. 

 

12.            Public
Reports; Use of Name.

 

The Foundation may
include information about this investment in its periodic public reports and may make the investment public at any time on its web
page and as part of press releases, public reports, speeches, newsletters and other public documents, and to the extent
required by applicable law or regulation. Any announcement of the Foundation Investment by any other party, including the Company or
Exscientia, their representatives, directors, stockholders, members, agents, or any investor, will require the Foundation’s
prior written approval.  Such parties will also obtain the Foundation’s prior written approval for any other use of the
Foundation’s name or logo in any respect; provided, however, that the Company may use the Foundation’s name for any uses
that have been pre-approved in writing by the Foundation.  Notwithstanding the foregoing, the Foundation’s name and logo
will not be used by any party in any manner to market, sell or otherwise promote the Company or Exscientia, or their products,
services and/or business.

 

Certain confidential information contained in this document, marked
by [****], has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private
or confidential.

 

     

     

    

 

13.            Indemnification. 

 

Exscientia will indemnify,
hold harmless, and defend the Foundation and its co-chairs, trustees, directors, officers, and employees (collectively, the “Indemnitees”)
from and against any and all third party causes of action, claims, suits, legal proceedings, judgments, settlements, damages, penalties,
losses, liabilities and costs (including reasonable attorneys’ fees and costs) (each a “Claim”) finally awarded
to such-third party by a court of competent jurisdiction against any of the Indemnitees or agreed to as part of a monetary settlement
of the Claim and arising out of or relating to (a) bodily injury or death directly caused by the activities or omissions of the
Company or any Company Affiliate, relating to the conduct of the Antiviral Program or the development of the Funded Developments (including
any failure to comply with applicable laws, regulations or rules in connection therewith), (b) any Claim that the Platform
Technology, any Funded Development, any Background IP or any product or service of the Company, Exscientia or one of their respective
Affiliates infringes, misappropriates or otherwise violates an Intellectual Property Right or other right of a third-party (provided
that the foregoing shall not apply to: (i) modifications of any of the foregoing made by a person or entity other than the Company,
Exscientia or their respective Affiliates after an Exercise Event if the infringement, misappropriation or violation would not have arisen
but for such modification; or (ii) by the combination, operation or use of any of the foregoing with any third party products, services,
hardware, software or technology if the infringement, misappropriation or violation would not have arisen but for such combination, operation
or use), or (c) the Company’s or any Company Affiliate’s fraud, gross negligence or willful misconduct. The Foundation
will give Exscientia prompt written notice of any Claim subject to indemnification pursuant to this Section 13; provided, that the
Foundation’s failure to promptly notify Exscientia will not affect Exscientia’s indemnification obligations except to the
extent that the Foundation’s delay prejudices Exscientia’s ability to defend the Claim. Exscientia will have sole control
over the defense and settlement of each and every Claim, with counsel of its own choosing which is reasonably acceptable to the Foundation;
provided, that Exscientia conducts the defense actively and diligently at the sole cost and expense of Exscientia and provided further
that Exscientia will not enter into any settlement that adversely affects any Indemnitee without the applicable Indemnitee’s prior
written consent, such consent not to be unreasonably withheld, conditioned or delayed. The Foundation will provide Exscientia, upon request,
with reasonable cooperation in connection with the defense and settlement of the Claim. Subject to Exscientia’s rights above to
control the defense and settlement of Claims, the Foundation and any Indemnitee may, at its own expense, employ separate counsel to monitor
and participate in the defense of any Claim under this Section 13. For the avoidance of doubt, Exscientia shall have no obligation
to indemnify the Foundation pursuant to this Section 13 to the extent the Claim arises out of the Foundation’s fraud, gross
negligence or willful misconduct. 

 

The parties will not be liable
to each other for any indirect, incidental, consequential, or special damages (including lost revenues, lost savings, or lost profits
suffered by such other party) suffered by such other party arising under or in connection with this Agreement, regardless of the form
of action, whether in contract or tort, including negligence of any kind, whether active or passive, and regardless of whether the party
knew of the possibility that such damages could result; provided, that to the extent an Indemnitee is entitled to be indemnified hereunder
for Claims of third parties and such third party has been awarded indirect, incidental, consequential, reliance, or special damages (including
lost revenues, lost savings, or lost profits), Exscientia’s indemnification obligations to the Indemnitee will extend to and include
such third party’s indirect, incidental, consequential, reliance, or special damages (including lost revenues, lost savings, or
lost profits).  The parties further agree that under no circumstances will any party be liable to the other party (or to any Indemnitee)
more than once for the same losses arising under or in connection with this Agreement. 

 

Certain confidential information contained in this document, marked
by [****], has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private
or confidential.

 

     

     

    

 

14.            Insurance. 

 

Exscientia agrees to maintain
insurance coverage sufficient to cover the activities, risks, and potential omissions in respect of the work contemplated by or in connection
with this Agreement in accordance with generally-accepted industry standards and as required by law. Exscientia will ensure all subcontractors
maintain insurance coverage consistent with this paragraph. 

 

15.            Compliance
with Laws and Requirements; Responsibility. 

 

Exscientia will comply
with (and cause its Affiliates to comply with) all applicable laws, regulations, and rules and will use commercially reasonable
efforts to not infringe, misappropriate, or violate the Intellectual Property Rights, privacy or publicity or other rights of any
third party. Exscientia will conduct, control, manage, and monitor all work performed in connection with or as contemplated by this
Agreement using the Foundation Investment in compliance with all applicable ethical, legal, regulatory, and safety requirements and
obtain and maintain all necessary approvals, consents, and reviews for such activities. If any work conducted by Exscientia in
connection with or as contemplated by this Agreement involves:

 

(a)            any
protected information (including personally identifiable, protected health, or third party confidential information), neither the Company
nor Exscientia will disclose this information to the Foundation without obtaining the Foundation’s prior written approval and all
necessary consents to disclose such information; 

 

(b)            children,
students, or vulnerable subjects, Exscientia will obtain any necessary consents and approvals unique to these subjects; or 

 

(c)            any
trial involving human subjects, Exscientia will adhere to current Good Clinical Practice as defined by the International Council on Harmonisation
(ICH) E-6 Standards (or local regulations if more stringent) and will obtain applicable trial insurance. 

 

The Company and Exscientia will be solely responsible
and liable for all activities related to the conduct of the Antiviral Program and development of the Antiviral Products. Any activities
by the Foundation or the Joint Steering Committee in reviewing documents and providing input or funding do not modify the Company’s
and Exscientia’s responsibility, including responsibility for determining and complying with the provisions of this Section 15. 

 

16.            Company
Assurance of Performance. 

 

The Company shall cause Exscientia to comply
in all respects with each of its representations, warranties, covenants, obligations, agreements and undertakings pursuant to or otherwise
in connection with this Agreement and the transactions contemplated by this Agreement. 

 

Certain confidential information contained in this document, marked
by [****], has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private
or confidential.

 

     

     

    

 

17.            Specific
Performance.

 

The Company and Exscientia acknowledge and agree
that the Foundation would be damaged irreparably in the event any of the provisions of this Agreement are not performed in accordance
with their specific terms or otherwise are breached or violated. Accordingly, the Company and Exscientia agree that, without posting
bond or other undertaking, the Foundation will be entitled to an injunction or injunctions to prevent breaches or violations of the provisions
of this Agreement and to enforce specifically this Agreement and the terms and provisions hereof in any action instituted in any court
having jurisdiction over the Company or Exscientia and the matter in addition to any other remedy to which it may be entitled, at law
or in equity. The Company and Exscientia further agree that, in the event of any action for specific performance in respect of such breach
or violation, it will not assert the defense that a remedy at law would be adequate. 

 

18.            Authority;
Governing Law. 

 

Each of the signatories below
covenants, represents and warrants that he, she or it had all authority necessary to execute this Agreement and that, on execution, this
Agreement will be fully binding and enforceable in accordance with its terms, and that no other consents or approvals of any other person
or third parties are required or necessary for this Agreement to be so binding. This Agreement will be governed by the laws of the state
of New York, United States, excluding its conflicts of laws provisions. 

 

19.            Dispute
Resolution

 

The parties will resolve
any dispute, controversy or claim arising out of or relating to this Agreement, or the breach, termination or invalidity hereof (“Dispute”)
in accordance with this Section 19.

 

(a)            Designated
Representatives; Escalation to CEOs. If a Dispute arises, the parties will each appoint a designated representative whose task
it will be to meet for the purpose of endeavoring to resolve such Dispute. The designated representatives shall meet as often as the
parties reasonably deem necessary to discuss the problem in an effort to resolve the Dispute without the necessity of any formal
proceeding. If such representatives are unable to resolve the Dispute within [****] after the Dispute is submitted to them, the
Dispute shall be immediately referred by written notice to the Chief Executive Officer of the Company and the President of Global
Health (or any equivalent successor position) or the Chief Executive Officer of the Foundation. No settlement reached under this
Section 19(a) shall be binding on the parties unless reduced to a writing signed by the parties. The existence and
substance of the negotiations pursuant to this Section 19(a) shall be considered confidential under this Agreement, shall
be treated as compromise and settlement negotiations for purposes of Federal Rule of Evidence 408 and any comparable provision,
and shall not be used by any party in any court, agency or tribunal in any country for any reason. If such officers are unable to
resolve such Dispute within [****] after the Dispute is submitted to them, then the Dispute shall be submitted to arbitration in
accordance with this Section 19.

 

Certain confidential information contained in this document, marked
by [****], has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private
or confidential.

 

     

     

    

 

(b)            Arbitration. 

 

(i)            Any
Dispute that has not been resolved pursuant to Section 19(a) shall be referred to the London Court of International Arbitration
for determination by arbitration in accordance with the LCIA Arbitration Rules in effect at the time of submitting the request for
arbitration. It is the intent of the parties that, barring extraordinary circumstances, the arbitration proceedings shall be concluded
within [****] from the date the arbitrator is confirmed. The parties may agree to extend this time limit or the arbitrator may do so
in its discretion for a period of up to an additional [****], if it determines that the interest of justice so requires. The arbitrator
shall use its best efforts to issue the final award or awards within such time period. Failure to adhere to this time limit shall not
be a basis for challenging the award. 

 

(ii)            The
governing law and seat of this arbitration agreement will be New York, United States. The physical location of the arbitration will be
in London, England. The arbitration shall be conducted by a single, neutral arbitrator who shall be experienced in the field of the Dispute
and shall have no ongoing business relationship with any party. Such arbitrator shall be selected by mutual agreement of the parties and
the parties will be entitled to select arbitrators that are not on the LCIA-established panel of arbitrators. If the parties are unable
to reach an agreement on the choice of arbitrator, then the arbitrator will be selected by the London Court of International Arbitration.
The arbitrator may grant legal, equitable and monetary relief and shall award to the prevailing party such party’s costs and expenses
incurred in connection with the arbitration and the collection of judgment, including reasonable attorneys’ fees. In no case, however,
shall indirect, incidental, consequential, or special damages (including lost revenues, lost savings, or lost profits) be awarded by the
arbitrator, except as permitted by Section 13. Judgment upon the award rendered by the arbitrator shall be binding, final and non-appealable
(absent manifest error) and may be entered and enforced in any court having jurisdiction thereof. The language used in the arbitration
proceedings shall be English.

 

(iii)            No
information concerning a Dispute and any related arbitration, beyond the names of the parties and the relief requested, may be unilaterally
disclosed to a third party by any party unless required by law. Any documentary or other evidence given by a party or witness in the
arbitration shall be treated as confidential by any party whose access to such evidence arises exclusively as a result of its participation
in the arbitration and shall not be disclosed to any third party (other than a witness or expert), except as may be required by law. 

 

(c)            Obligation
to Continue Performance Pending Resolution of a Dispute. The parties agree to continue performing their obligations under this Agreement
pending the resolution of any Dispute that is being resolved hereunder unless and until such obligations are terminated or expire in
accordance with the provisions of this Agreement. 

 

(d)            Judicial
Procedure. Notwithstanding the foregoing, and without waiting for the expiration of the time periods set forth above, each party
shall have the right to apply to any court of competent jurisdiction for appropriate interim or provisional relief, as necessary to protect
its rights or property. Furthermore, nothing herein shall prevent the parties from resorting to a court of competent jurisdiction in
those instances where preliminary injunctive relief would be appropriate, pending final resolution of the Dispute through arbitration.
Nothing in this Section 19 shall be construed to prevent a party from instituting formal proceedings at any time to avoid the expiration
of any statute of limitations period or to preserve a superior position with respect to other creditors. For the avoidance of doubt,
to the extent this Agreement permits the parties to apply for relief to or institute a proceeding in a court of competent jurisdiction,
nothing in this Agreement or any other Investment Document will constitute a waiver of the right to a jury trial in such proceeding. 

 

Certain confidential information contained in this document, marked
by [****], has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private
or confidential.

 

     

     

    

 

20.            Termination 

 

This Agreement will terminate
and cease to have any effect if the Foundation Investment under the Investment Agreement has not closed by December 31, 2021 (or
such later date as may be agreed in writing between the Company and the Foundation) unless the Company, Exscientia and the Foundation
agree otherwise in writing. Any termination of this Agreement in accordance with this Section 20 shall be without prejudice to any
accrued rights or obligations of any party to this Agreement.

 

21.            Entire
Agreement; Modification. 

 

The terms and conditions
set forth in this Agreement are in addition to the provisions stated in the other Investment Documents and the terms and conditions of
this Agreement will prevail over any inconsistent provision in any other Investment Document and supersede any prior understandings and
agreements, either oral or in writing, between the parties with respect to the subject matter hereof. No change, modification or waiver
of any term or condition of this Agreement will be valid unless it is in writing, it is signed by the party to be bound, and it expressly
refers to this Agreement. For the avoidance of doubt, nothing in this Agreement will limit or restrict the Foundation’s rights
or Exscientia’s obligations pursuant to any grant agreements between Exscientia and the Foundation (including Investment ID INV-031996
and Investment ID INV-004656). 

 

22.            Severability. 

 

The invalidity or unenforceability
of any provision of this Agreement will in no way affect the validity or enforceability of any other provision. 

 

23.            Counterparts. 

 

This Agreement may be executed
in one or more counterparts, each of which will be deemed an original, but all of which will be deemed to be and constitute one and the
same instrument. 

 

Certain confidential information contained in this document, marked
by [****], has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private
or confidential.

 

     

     

    

 

24.            Construction. 

 

Section headings are
not to be considered part of this Agreement, are included solely for convenience, are not intended to be full or accurate descriptions
of the content thereof and will not affect the construction of this Agreement. The words “include,” “includes”
and “including” will be considered to be followed by the words “without limitation”.

 

[Signature Page Follows]

  

Certain confidential information contained in this document, marked
by [****], has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private
or confidential.

 

     

     

    

 

The parties
have caused this Agreement to be executed as of the date first set forth above. 

 

	Exscientia
    Limited	 	Exscientia
    AI Limited 
	 	 	 
	By:	 	 	By: 	          

	Name:	 	 	Name: 	 

	Title:	 	 	Title: 	 

	 	 	 
	Bill &
    Melinda Gates Foundation 	 	 
	 	 	 
	By: 	         	 	 

	Name:	 	 	 	 

	Title:	 	 	 	 

 

Certain confidential information contained in this document, marked
by [****], has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private
or confidential.

 

     

     

    

 

Appendix A: Developing Countries 

Appendix B: Existing Agreements 

Appendix C: Target Diseases and Conditions 

Appendix D: Scope of Work; Initial Antiviral Projects 

Appendix E: Officer’s Certificate 

Appendix F: Officer’s Certificate 

 

Certain confidential information contained in this document, marked
by [****], has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private
or confidential.Exhibit 10.13

 

EXSCIENTIA LIMITED

 

REGISTRATION RIGHTS AGREEMENT 

 

               ,
2021

 

THIS
REGISTRATION RIGHTS AGREEMENT (the “Agreement”) is entered into as of the date above, by and among
Exscientia Limited (to be reorganised as Exscientia plc), a company incorporated in England and Wales under company number 13483814
and having its registered office at The Schrodinger Building, Heatley Road, Oxford Science Park, Oxford OX4 4GE (the “Company”)
and the undersigned entities and individuals listed on Exhibit A hereto, referred to hereinafter as the “Rights Holders”
and each individually as an “Rights Holder.”

 

WHEREAS, pursuant to that certain Shareholders’
Agreement dated August 10, 2021, between each of the Subscribers, Non-Investing Shareholders and Manager (as each is defined in such agreement)
listed on Schedule 1 thereto and the Company (the Shareholders’ Agreement), the Company and the Investors (as defined
in the Shareholders' Agreement) agreed to enter into a registration rights agreement in advance of, but subject to, an IPO (as defined
in the Shareholders’ Agreement);

 

WHEREAS, subject to re-registration as
a public limited company, the Company is contemplating an initial public offering in the United States of American Depositary Shares (“ADSs),
each ADS representing one of the Company’s ordinary shares (the “Proposed IPO”);

 

WHEREAS, pursuant to that certain Subscription
Agreement dated September 1, 2021, between the Bill & Melinda Gates Foundation (the “Gates Foundation”)
and the Company (the “Subscription Agreement”), the Company and the Gates Foundation agreed that the Company
would provide the Gates Foundation registration rights on substantially the same terms as contemplated in the Shareholders’ Agreement;

 

WHEREAS, the Company’s board of directors
(the “Board”) has agreed to provide registration rights to Andrew Hopkins; and

 

WHEREAS, the Rights Holders and the Company
desire to enter into this Agreement to set forth the registration rights of the parties hereto that will be in effect after the consummation
of the Proposed IPO, and in doing so, replace and supersede in their entirety any provisions in the Shareholders’ Agreement and
the Subscription Agreement related to registration rights.

 

NOW, THEREFORE, in consideration of these
premises and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto
agree as follows:

 

SECTION 1. GENERAL. 

 

1.1 Effective Date. The effective date
of this Agreement is the date set forth above. However, the effective date of the grant of registration rights described herein is the
date of the underwriting agreement related to the Proposed IPO. Only if, and when, such underwriting agreement has become effective, will
the registration rights described herein become effective.

 

1.2 Definitions. As used in this Agreement
the following terms shall have the following respective meanings:

 

(a) “ADSs” means American
Depositary Shares, each representing one Ordinary Share.

 

(b) “Depositary”
means the depositary engaged by the Company for the issuance and transfer of ADSs.

 

(c) “Exchange Act” means
the Securities Exchange Act of 1934, as amended.

 

     

     

    

 

(d) “Form F-3” means
such form under the Securities Act as in effect on the date hereof or any successor or similar registration form under the Securities
Act subsequently adopted by the SEC which permits inclusion or incorporation of substantial information by reference to other documents
filed by the Company with the SEC.

 

(e) “Holder” means any
person owning of record Registrable Securities that have not been sold to the public or any assignee of record of such Registrable Securities.

 

(f) “IPO” means the
Company’s first firm commitment underwritten public offering of its securities registered under the Securities Act.

 

(g) “Ordinary Shares”
refer to the ordinary shares in the issued share capital of the Company following the closing of the IPO.

 

(h) “Register,” “registered,”
and “registration” refer to a registration effected by preparing and filing a registration statement in compliance
with the Securities Act, and the declaration or ordering of effectiveness of such registration statement or document.

 

(i) “Registrable Securities”
means the Ordinary Shares held by the Rights Holders at the closing of an IPO and the completion of any related corporate reorganization,
or any ADSs issued in respect of such Ordinary Shares. Notwithstanding the foregoing, Registrable Securities shall not include any securities
(i) sold by a person to the public either pursuant to a registration statement or Rule 144 or (ii) sold in a private transaction in which
the transferor’s rights under Section 2 of this Agreement are not assigned.

 

(j) “Registrable Securities then outstanding”
shall be the number of Ordinary Shares that are Registrable Securities and either (a) are then issued and outstanding or (b) are
issuable pursuant to then exercisable or convertible securities.

 

(k) “Registration Expenses”
shall mean all expenses incurred by the Company in complying with Sections 2.2, 2.3 and 2.4 hereof, including, without limitation,
all registration and filing fees, printing expenses, fees and disbursements of counsel for the Company, reasonable fees and disbursements
not to exceed sixty thousand dollars ($60,000) of a single special counsel for the Holders, blue sky fees and expenses and the expense
of any special audits incident to or required by any such registration (but excluding the compensation of regular employees of the Company
which shall be paid in any event by the Company).

 

(l) “SEC” or “Commission”
means the Securities and Exchange Commission.

 

(m) “Securities Act” shall
mean the Securities Act of 1933, as amended.

 

(n) “Selling Expenses” shall
mean all underwriting discounts and selling commissions applicable to the sale.

 

(o) “Shares” shall mean
the Ordinary Shares held from time to time by the Rights Holders listed on Exhibit A hereto and their permitted assigns.

 

(p) “Special Registration Statement”
shall mean (i) a registration statement relating to any employee benefit plan or (ii) with respect to any corporate reorganization or
transaction under Rule 145 of the Securities Act, any registration statements related to the issuance or resale of securities issued in
such a transaction or (iii) a registration related to shares issued upon conversion of debt securities.

 

SECTION
2. REGISTRATION; RESTRICTIONS ON TRANSFER.

 

2.1 Demand Registration. 

 

(a) Subject to the conditions of this
Section 2.1, if the Company shall receive a written request from the Holders who together hold in aggregate not less than 50% of the
Registrable Securities then outstanding (the “Initiating Holders”) that the Company file a registration
statement under the Securities Act covering the registration of at least 50% of the Registrable Securities then outstanding (or a
lesser percent if the anticipated aggregate offering price, net of underwriting discounts and commissions, would exceed
$10,000,000), then the Company shall, within thirty (30) days of the receipt thereof, give written notice of such request to all
Holders, and subject to the limitations of this Section 2.1, effect, as expeditiously as reasonably possible, the registration under
the Securities Act of all Registrable Securities that all Holders request to be registered.

 

     

     

    

 

(b) If the Initiating Holders intend to
distribute the Registrable Securities covered by their request by means of an underwriting, they shall so advise the Company as a part
of their request made pursuant to this Section 2.1 or any request pursuant to Section 2.3 and the Company shall include such information
in the written notice referred to in Section 2.1(a) or Section 2.3(a), as applicable. In such event, the right of any Holder to include
its Registrable Securities in such registration shall be conditioned upon such Holder’s participation in such underwriting and the
inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute
their securities through such underwriting shall enter into an underwriting agreement in customary form with the underwriter or underwriters
selected for such underwriting by the Holders of a majority of the Registrable Securities held by all Initiating Holders (which underwriter
or underwriters shall be reasonably acceptable to the Company). Notwithstanding any other provision of this Section 2.1 or Section 2.3,
if the underwriter advises the Company that marketing factors require a limitation of the number of securities to be underwritten (including
Registrable Securities) then the Company shall so advise all Holders of Registrable Securities that would otherwise be underwritten pursuant
hereto, and the number of shares that may be included in the underwriting shall be allocated to the Holders of such Registrable Securities
on a pro rata basis based on the number of Registrable Securities held by all such Holders (including the Initiating Holders. Any
Registrable Securities excluded or withdrawn from such underwriting shall be withdrawn from the registration.

 

(c) The Company shall not be required to
effect a registration pursuant to this Section 2.1:

 

(i) prior to the date one hundred eighty
(180) days following the effective date of the registration statement pertaining to the IPO or after five (5) years after the date of this Agreement;

 

(ii) after the Company has effected two
(2) registrations pursuant to this Section 2.1, and such registrations have been declared or ordered effective;

 

(iii) if, within thirty (30) days of receipt
of a written request from Initiating Holders pursuant to Section 2.1(a), the Company gives notice to the Holders of the Company’s
intention to file a registration statement for a public offering, other than pursuant to a Special Registration Statement, within ninety
(90) days;

 

(iv) if the Company shall furnish to Holders
requesting a registration statement pursuant to this Section 2.1 a certificate signed by the Chairman of the Board (or, in the absence
of a Chairman of the Board, a lead independent director or director exercising a similar function) stating that in the good faith judgment
of the Board of Directors of the Company, it would be seriously detrimental to the Company and its shareholders for such registration
statement to be effected at such time, in which event the Company shall have the right to defer such filing for a period of not more than
one hundred twenty (120) days after receipt of the request of the Initiating Holders;

 

(v) if the Initiating Holders propose to
dispose of shares of Registrable Securities that may be immediately registered on Form F-3 pursuant to a request made pursuant to Section
2.3 below; or

 

(vi) in any particular jurisdiction in
which the Company would be required to qualify to do business or to execute a general consent to service of process in effecting such
registration, qualification or compliance.

 

2.2 Piggyback Registrations. The
Company shall notify all Holders of Registrable Securities in writing at least ten (10) days prior to the filing of any registration
statement under the Securities Act for purposes of a public offering of securities of the Company (including, but not limited to,
registration statements relating to secondary offerings of securities of the Company, but excluding Special Registration Statements)
and will afford each such Holder an opportunity to include in such registration statement all or part of such Registrable Securities
held by such Holder. Each Holder desiring to include in any such registration statement all or any part of the Registrable
Securities held by it shall, within five (5) days after the above-described notice from the Company, so notify the Company in
writing. Such notice shall state the intended method of disposition of the Registrable Securities by such Holder. If a Holder
decides not to include all of its Registrable Securities in any registration statement thereafter filed by the Company, such Holder
shall nevertheless continue to have the right to include any Registrable Securities in any subsequent registration statement or
registration statements as may be filed by the Company with respect to offerings of its securities, all upon the terms and
conditions set forth herein.

 

     

     

    

 

(a) Underwriting. If the registration statement
of which the Company gives notice under this Section 2.2 is for an underwritten offering, the Company shall so advise the Holders of Registrable
Securities. In such event, the right of any such Holder to include Registrable Securities in a registration pursuant to this Section 2.2
shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable
Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their Registrable Securities through
such underwriting shall enter into an underwriting agreement in customary form with the underwriter or underwriters selected for such
underwriting by the Company. Notwithstanding any other provision of this Agreement, if the Company determines in good faith, based on
consultation with the underwriter, that marketing factors require a limitation of the number of shares to be underwritten, the number
of shares that may be included in the underwriting shall be allocated, first, to the Company; and second, to the Holders on a pro rata
basis based on the total number of Registrable Securities held by the Holders; and third, to any shareholder of the Company (other than
a Holder) on a pro rata basis; provided, however, that no such reduction shall reduce the amount of securities of the selling Holders
included in the registration below thirty percent (30%) of the total amount of securities included in such registration, unless such offering
is the IPO and such registration does not include shares of any other selling shareholders, in which event any or all of the Registrable
Securities of the Holders may be excluded in accordance with the immediately preceding clause. If any Holder disapproves of the terms
of any such underwriting, such Holder may elect to withdraw therefrom by written notice to the Company and the underwriter, delivered
at least ten (10) business days prior to the effective date of the registration statement. Any Registrable Securities excluded or withdrawn
from such underwriting shall be excluded and withdrawn from the registration. For any Holder which is a partnership, limited liability
company or corporation, the partners, retired partners, members, retired members and stockholders of such Holder, or the estates and family
members of any such partners, retired partners, members and retired members and any trusts for the benefit of any of the foregoing person
shall be deemed to be a single “Holder,” and any pro rata reduction with respect to such “Holder” shall
be based upon the aggregate amount of shares carrying registration rights owned by all entities and individuals included in such “Holder,”
as defined in this sentence.

 

(b) Right to Terminate Registration. The
Company shall have the right to terminate or withdraw any registration initiated by it under this Section 2.2 whether or not any Holder
has elected to include securities in such registration, and shall promptly notify any Holder that has elected to include shares in such
registration of such termination or withdrawal. The Registration Expenses of such withdrawn registration shall be borne by the Company
in accordance with Section 2.4 hereof.

 

2.3 Form F-3 Registration. In case the
Company shall receive from any Holder or Holders of Registrable Securities who together hold in aggregate not less than 10% of the Registrable
Securities then outstanding a written request or requests that the Company effect a registration on Form F-3 (or any successor to Form
F-3) or any similar short-form registration statement and any related qualification or compliance with respect to all or a part of the
Registrable Securities owned by such Holder or Holders, the Company will:

 

(a) promptly give written notice of the
proposed registration, and any related qualification or compliance, to all other Holders of Registrable Securities; and

 

(b) as soon as practicable, effect such
registration and all such qualifications and compliances as may be so requested and as would permit or facilitate the sale and distribution
of all or such portion of such Holder’s or Holders’ Registrable Securities as are specified in such request, together with
all or such portion of the Registrable Securities of any other Holder or Holders joining in such request as are specified in a written
request given within ten (10) days after receipt of such written notice from the Company; provided, however, that the Company shall
not be obligated to effect any such registration, qualification or compliance pursuant to this Section 2.3:

 

(i) if Form F-3 is not available for such
offering by the Holders, or

 

(ii) if the Holders, together with the
holders of any other securities of the Company entitled to inclusion in such registration, propose to sell Registrable Securities and
such other securities (if any) at an aggregate price to the public of less than one million dollars ($1,000,000), or

 

     

     

    

 

(iii) if, within thirty (30) days of receipt
of a written request from any Holder or Holders pursuant to this Section 2.3, the Company gives notice to such Holder or Holders of the
Company’s intention to make a public offering within ninety (90) days, other than pursuant to a Special Registration Statement;

 

(iv) if the Company shall furnish to the
Holders a certificate signed by the Chairman of the Board (or, in the absence of a Chairman of the Board, a lead independent director
or director exercising a similar function) of the Company stating that in the good faith judgment of the Board, it would be seriously
detrimental to the Company and its shareholders for such Form F-3 registration to be effected at such time, in which event the Company
shall have the right to defer the filing of the Form F-3 registration statement for a period of not more than one hundred twenty (120)
days after receipt of the request of the Holder or Holders under this Section 2.3; or

 

(v) if the Company has, within the twelve
(12) month period preceding the date of such request, already effected two (2) registrations on Form F-3 for the Holders pursuant to this
Section 2.3, or

 

(vi) in any particular jurisdiction in
which the Company would be required to qualify to do business or to execute a general consent to service of process in effecting such
registration, qualification or compliance.

 

(c) Subject to the foregoing, the Company
shall file a Form F-3 registration statement covering the Registrable Securities and other securities so requested to be registered as
soon as practicable after receipt of the requests of the Holders. Registrations effected pursuant to this Section 2.3 shall not be counted
as demands for registration or registrations effected pursuant to Section 2.1.

 

2.4 Expenses of Registration. Except as
specifically provided herein, all Registration Expenses incurred in connection with any registration, qualification or compliance pursuant
to Section 2.1, 2.2 or 2.3 herein shall be borne by the Company. All Selling Expenses incurred in connection with any registrations hereunder,
shall be borne by the holders of the securities so registered pro rata on the basis of the number of shares so registered. The
Company shall not, however, be required to pay for expenses of any registration proceeding begun pursuant to Section 2.1 or 2.3, the request
of which has been subsequently withdrawn by the Initiating Holders unless (a) the withdrawal is based upon material adverse information
concerning the Company of which the Initiating Holders were not aware at the time of such request or (b) the Holders of a majority of
Registrable Securities agree to deem such registration to have been effected as of the date of such withdrawal for purposes of determining
whether the Company shall be obligated pursuant to Section 2.1(c) or 2.3(b)(v), as applicable, to undertake any subsequent registration,
in which event such right shall be forfeited by all Holders). If the Holders are required to pay the Registration Expenses, such expenses
shall be borne by the holders of securities (including Registrable Securities) requesting such registration in proportion to the number
of shares for which registration was requested. If the Company is required to pay the Registration Expenses of a withdrawn offering pursuant
to clause (a) above, then such registration shall not be deemed to have been effected for purposes of determining whether the Company
shall be obligated pursuant to Section 2.1(c) or 2.3(b)(v), as applicable, to undertake any subsequent registration.

 

2.5 Obligations of the Company. Whenever
required to effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible:

 

(a) prepare and file with the SEC a
registration statement with respect to such Registrable Securities and use all reasonable efforts to cause such registration
statement to become effective, and, upon the request of the Holders of a majority of the Registrable Securities registered
thereunder, keep such registration statement effective for up to thirty (30) days or, if earlier, until the Holder or Holders have
completed the distribution related thereto; provided, however, that at any time, upon written notice to the participating Holders
and for a period not to exceed sixty (60) days thereafter (the “Suspension Period”), the Company may delay
the filing or effectiveness of any registration statement or suspend the use or effectiveness of any registration statement (and the
Initiating Holders hereby agree not to offer or sell any Registrable Securities pursuant to such registration statement during the
Suspension Period) if the Company reasonably believes that there is or may be in existence material nonpublic information or events
involving the Company, the failure of which to be disclosed in the prospectus included in the registration statement could result in
a Violation (as defined below). In the event that the Company shall exercise its right to delay or suspend the filing or
effectiveness of a registration hereunder, the applicable time period during which the registration statement is to remain effective
shall be extended by a period of time equal to the duration of the Suspension Period. The Company may extend the Suspension Period
for an additional consecutive sixty (60) days with the consent of the holders of a majority of the Registrable Securities registered
under the applicable registration statement, which consent shall not be unreasonably withheld. If so directed by the Company, all
Holders registering shares under such registration statement shall (i) not offer to sell any Registrable Securities pursuant to the
registration statement during the period in which the delay or suspension is in effect after receiving notice of such delay or
suspension; and (ii) use their best efforts to deliver to the Company (at the Company’s expense) all copies, other than
permanent file copies then in such Holders’ possession, of the prospectus relating to such Registrable Securities current at
the time of receipt of such notice. Notwithstanding the foregoing, the Company shall not be required to file, cause to become
effective or maintain the effectiveness of any registration statement other than a registration statement on Form F-3 that
contemplates a distribution of securities on a delayed or continuous basis pursuant to Rule 415 under the Securities Act.

 

     

     

    

 

(b) Prepare and file with the SEC such
amendments and supplements to such registration statement and the prospectus used in connection with such registration statement as may
be necessary to comply with the provisions of the Securities Act with respect to the disposition of all securities covered by such registration
statement for the period set forth in subsection (a) above.

 

(c) Furnish to the Holders such number
of copies of a prospectus, including a preliminary prospectus, in conformity with the requirements of the Securities Act, and such other
documents as they may reasonably request in order to facilitate the disposition of Registrable Securities owned by them.

 

(d) Use its reasonable efforts to register
and qualify the securities covered by such registration statement under such other securities or blue sky laws of such jurisdictions as
shall be reasonably requested by the Holders; provided that the Company shall not be required in connection therewith or as a condition
thereto to qualify to do business or to file a general consent to service of process in any such states or jurisdictions.

 

(e) In the event of any underwritten public
offering, enter into and perform its obligations under an underwriting agreement, in usual and customary form, with the managing underwriter(s)
of such offering. Each Holder participating in such underwriting shall also enter into and perform its obligations under such an agreement.

 

(f) Notify each Holder of Registrable Securities
covered by such registration statement at any time when a prospectus relating thereto is required to be delivered under the Securities
Act of the happening of any event as a result of which the prospectus included in such registration statement, as then in effect, includes
an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements
therein not misleading in the light of the circumstances then existing. The Company will use reasonable efforts to amend or supplement
such prospectus in order to cause such prospectus not to include any untrue statement of a material fact or omit to state a material fact
required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then existing.

 

(g) Use its reasonable efforts to furnish,
on the date that such Registrable Securities are delivered to the underwriters for sale, if such securities are being sold through underwriters,
(i) an opinion, dated as of such date, of the counsel representing the Company for the purposes of such registration, in form and substance
as is customarily given to underwriters in an underwritten public offering, addressed to the underwriters, if any, and (ii) a letter,
dated as of such date, from the independent certified public accountants of the Company, in form and substance as is customarily given
by independent certified public accountants to underwriters in an underwritten public offering addressed to the underwriters.

 

2.6 Delay of Registration; Furnishing Information.

 

(a) No Holder shall have any right to obtain
or seek an injunction restraining or otherwise delaying any such registration as the result of any controversy that might arise with respect
to the interpretation or implementation of this Section 2.

 

(b) It shall be a condition precedent to
the obligations of the Company to take any action pursuant to Section 2.1, 2.2 or 2.3 that the selling Holders shall furnish to the Company
such information regarding themselves, the Registrable Securities held by them and the intended method of disposition of such securities
as shall be required to effect the registration of their Registrable Securities.

 

     

     

    

 

(c) The Company shall have no obligation
with respect to any registration requested pursuant to Section 2.1 or Section 2.3 if the number of shares or the anticipated aggregate
offering price of the Registrable Securities to be included in the registration does not equal or exceed the number of shares or the anticipated
aggregate offering price required to originally trigger the Company’s obligation to initiate such registration as specified in Section
2.1 or Section 2.3, whichever is applicable.

 

2.7 Indemnification. In the event any Registrable
Securities are included in a registration statement under Sections 2.1, 2.2 or 2.3:

 

(a) To the extent permitted by law, the
Company will indemnify and hold harmless each Holder, the partners, members, officers and directors of each Holder, any underwriter (as
defined in the Securities Act) for such Holder and each person, if any, who controls such Holder or underwriter within the meaning of
the Securities Act or the Exchange Act, against any losses, claims, damages, or liabilities (joint or several) to which they may become
subject under the Securities Act, the Exchange Act or other U.S. federal or state law, insofar as such losses, claims, damages or liabilities
(or actions in respect thereof) arise out of or are based upon any of the following statements, omissions or violations (collectively
a “Violation”) by the Company: (i) any untrue statement or alleged untrue statement of a material fact contained
in such registration statement or incorporated reference therein, including any preliminary prospectus or final prospectus contained therein
or any amendments or supplements thereto, (ii) the omission or alleged omission to state therein a material fact required to be stated
therein, or necessary to make the statements therein not misleading, or (iii) any violation or alleged violation by the Company of the
Securities Act, the Exchange Act, any state securities law or any rule or regulation promulgated under the Securities Act, the Exchange
Act or any state securities law in connection with the offering covered by such registration statement; and the Company will reimburse
each such Holder, partner, member, officer, director, underwriter or controlling person for any legal or other expenses reasonably incurred
by them in connection with investigating or defending any such loss, claim, damage, liability or action; provided however, that
the indemnity agreement contained in this Section 2.7(a) shall not apply to amounts paid in settlement of any such loss, claim, damage,
liability or action if such settlement is effected without the consent of the Company, which consent shall not be unreasonably withheld,
nor shall the Company be liable in any such case for any such loss, claim, damage, liability or action to the extent that it arises out
of or is based upon a Violation which occurs in reliance upon and in conformity with written information furnished expressly for use in
connection with such registration by such Holder, partner, member, officer, director, underwriter or controlling person of such Holder.

 

(b) To the extent permitted by law, each
Holder will, if Registrable Securities held by such Holder are included in the securities as to which such registration qualifications
or compliance is being effected, indemnify and hold harmless the Company, each of its directors, its officers and each person, if any,
who controls the Company within the meaning of the Securities Act, any underwriter and any other Holder selling securities under such
registration statement or any of such other Holder’s partners, directors or officers or any person who controls such Holder, against
any losses, claims, damages or liabilities (joint or several) to which the Company or any such director, officer, controlling person,
underwriter or other such Holder, or partner, director, officer or controlling person of such other Holder may become subject under the
Securities Act, the Exchange Act or other U.S. federal or state law, insofar as such losses, claims, damages or liabilities (or actions
in respect thereto) arise out of or are based upon any of the following statements: (i) any untrue statement or alleged untrue statement
of a material fact contained in such registration statement or incorporated reference therein, including any preliminary prospectus or
final prospectus contained therein or any amendments or supplements thereto, (ii) the omission or alleged omission to state therein a
material fact required to be stated therein, or necessary to make the statements therein not misleading, or (iii) any violation or alleged
violation by the Company of the Securities Act (collectively, a “Holder Violation”), in each case to the extent
(and only to the extent) that such Holder Violation occurs in reliance upon and in conformity with written information furnished by such
Holder under an instrument duly executed by such Holder and stated to be specifically for use in connection with such registration; and
each such Holder will reimburse any legal or other expenses reasonably incurred by the Company or any such director, officer, controlling
person, underwriter or other Holder, or partner, officer, director or controlling person of such other Holder in connection with investigating
or defending any such loss, claim, damage, liability or action if it is judicially determined that there was such a Holder Violation;
provided, however, that the indemnity agreement contained in this Section 2.7(b) shall not apply to amounts paid in settlement
of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the Holder, which consent shall
not be unreasonably withheld; provided further, that in no event shall any indemnity under this Section 2.7 exceed the net proceeds
from the offering received by such Holder.

 

     

     

    

 

(c) Promptly after receipt by an indemnified
party under this Section 2.7 of notice of the commencement of any action (including any governmental action), such indemnified party will,
if a claim in respect thereof is to be made against any indemnifying party under this Section 2.7, deliver to the indemnifying party a
written notice of the commencement thereof and the indemnifying party shall have the right to participate in, and, to the extent the indemnifying
party so desires, jointly with any other indemnifying party similarly noticed, to assume the defense thereof with counsel mutually satisfactory
to the parties; provided, however, that an indemnified party shall have the right to retain its own counsel, with the fees and
expenses thereof to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the indemnifying
party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented
by such counsel in such proceeding. The failure to deliver written notice to the indemnifying party within a reasonable time of the commencement
of any such action shall relieve such indemnifying party of any liability to the indemnified party under this Section 2.7 to the extent,
and only to the extent, prejudicial to its ability to defend such action, but the omission so to deliver written notice to the indemnifying
party will not relieve it of any liability that it may have to any indemnified party otherwise than under this Section 2.7.

 

(d) If the indemnification provided for
in this Section 2.7 is held by a court of competent jurisdiction to be unavailable to an indemnified party with respect to any losses,
claims, damages or liabilities referred to herein, the indemnifying party, in lieu of indemnifying such indemnified party thereunder,
shall to the extent permitted by applicable law contribute to the amount paid or payable by such indemnified party as a result of such
loss, claim, damage or liability in such proportion as is appropriate to reflect the relative fault of the indemnifying party on the one
hand and of the indemnified party on the other in connection with the Violation(s) or Holder Violation(s) that resulted in such loss,
claim, damage or liability, as well as any other relevant equitable considerations. The relative fault of the indemnifying party and of
the indemnified party shall be determined by a court of law by reference to, among other things, whether the untrue or alleged untrue
statement of a material fact or the omission to state a material fact relates to information supplied by the indemnifying party or by
the indemnified party and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such
statement or omission; provided, that in no event shall any contribution by a Holder hereunder exceed the proceeds from
the offering received by such Holder.

 

(e) The obligations of the Company and
Holders under this Section 2.7 shall survive completion of any offering of Registrable Securities in a registration statement and, with
respect to liability arising from an offering to which this Section 2.7 would apply that is covered by a registration filed before termination
of this Agreement, such termination. No indemnifying party, in the defense of any such claim or litigation, shall, except with the consent
of each indemnified party, consent to entry of any judgment or enter into any settlement which does not include as an unconditional term
thereof the giving by the claimant or plaintiff to such indemnified party of a release from all liability in respect to such claim or
litigation.

 

2.8 Assignment of Registration Rights. The
rights to cause the Company to register Registrable Securities pursuant to this Section 2 may be assigned by a Holder to a transferee
or assignee of Registrable Securities (for so long as such shares remain Registrable Securities) that (a) is a subsidiary, parent, general
partner, limited partner, retired partner, member or retired member of a Holder that is a corporation, partnership or limited liability
company or (b) is a Holder’s family member or trust for the benefit of an individual Holder; provided, however, (i) the transferor
shall, within ten (10) days after such transfer, furnish to the Company written notice of the name and address of such transferee or assignee
and the securities with respect to which such registration rights are being assigned and (ii) such transferee shall agree to be subject
to all restrictions set forth in this Agreement.

 

2.9 Agreement to Furnish Information.
If requested by the Company or the representative of the underwriters of the ordinary shares (or other securities) of the Company, each
Holder shall provide, within five (5) days of such request, such information as may be required by the Company or such representative
in connection with the completion of any public offering of the Company's securities pursuant to a registration statement filed under
the Securities Act. The obligations described in this Section 2.10 shall not apply to a Special Registration Statement. In order to enforce
the foregoing covenant, the Company may impose stop-transfer instructions with respect to such ordinary shares (or other securities)
until the end of such period. Each Holder agrees that any transferee of any shares of Registrable Securities shall be bound by Section
2.9. The underwriters of the Company's shares are intended third party beneficiaries of Section 2.9 and shall have the right, power and
authority to enforce the provisions hereof as though they were a party hereto.

 

     

     

    

 

2.10 Termination of Registration Rights.
The right of any Holder to request registration or inclusion of Registrable Securities in any registration pursuant to Section 2.1, Section
2.2, or Section 2.3 hereof shall terminate upon such time as all Registrable Securities of the Company issuable or issued upon conversion
of the Shares held by and issuable to such Holder (and its affiliates) may be sold pursuant to Rule 144 during any ninety (90) day period.
Upon such termination, such shares shall cease to be “Registrable Securities” hereunder for all purposes.

 

2.11 Exchange of Ordinary Shares into ADSs.
To the extent that the Company causes ADSs to be issued in an IPO and to the extent permitted by applicable law, following an IPO and
as requested by the Rights Holders, the Company shall deliver any instruction, certificate, consent or other similar item reasonably requested
by the Depositary to allow the Rights Holders to convert their Ordinary Shares to ADSs (for sale under this Agreement or otherwise), provided
that the Rights Holders shall not deposit such Ordinary Shares in exchange for ADSs at any time at which to do so would violate obligations
under any lock-up agreement entered into in connection with an offering by the Company, including the IPO. For the avoidance of doubt,
the forgoing shall not require the Company to pay any fee to the Depositary and is not a guarantee or other assurance of performance by
the Depositary.

 

2.12 Obligation to Register ADSs. Notwithstanding
anything to the contrary herein, unless the Company has previously caused the Ordinary Shares to be listed on a national securities exchange
or trading system in the United States (it being acknowledged that the Company shall have no obligation to so list the Ordinary Shares)
and a market in the United States for Ordinary Shares not held in the form of ADSs exists, then in any registration pursuant to this Agreement
any Registrable Securities registered and sold pursuant thereto shall be in the form of ADSs.

 

SECTION
3. MISCELLANEOUS. 

 

3.1 Governing Law. This Agreement and any
dispute or claims relating to it or its subject matter (including any non-contractual claims) shall be governed by and construed under
the laws of England and Wales and each party irrevocably submits to the jurisdiction of the courts of England and Wales.

 

3.2 Successors and Assigns. Except as otherwise
expressly provided herein, the provisions hereof shall inure to the benefit of, and be binding upon, the parties hereto and their respective
successors, assigns, heirs, executors, and administrators and shall inure to the benefit of and be enforceable by each person who shall
be a holder of Registrable Securities from time to time; provided, however, that prior to the receipt by the Company of adequate
written notice of the transfer of any Registrable Securities specifying the full name and address of the transferee, the Company may deem
and treat the person listed as the holder of such shares in its records as the absolute owner and holder of such shares for all purposes,
including the payment of dividends or any redemption price.

 

3.3 Entire Agreement. This Agreement constitutes
the full and entire understanding and agreement between the parties with regard to the subjects hereof and no party shall be liable or
bound to any other in any manner by any oral or written representations, warranties, covenants and agreements except as specifically set
forth herein and therein. Each party expressly represents and warrants that it is not relying on any oral or written representations,
warranties, covenants or agreements outside of this Agreement.

 

3.4 Severability. In the event one or more
of the provisions of this Agreement should, for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity,
illegality, or unenforceability shall not affect any other provisions of this Agreement, and this Agreement shall be construed as if such
invalid, illegal or unenforceable provision had never been contained herein.

 

     

     

    

 

3.5 Amendment and Waiver.

 

(a) Except as otherwise expressly provided,
this Agreement may be amended or modified, and the obligations of the Company and the rights of the Holders under this Agreement may be
waived, only upon the written consent of the Company and the holders of at least a majority of the then-outstanding Registrable Securities.

 

(b) For the purposes of determining the
number of Holders or Rights Holders entitled to vote or exercise any rights hereunder, the Company shall be entitled to rely solely on
the list of record holders of its shares as maintained by or on behalf of the Company.

 

3.6 Delays or Omissions. It is agreed that
no delay or omission to exercise any right, power, or remedy accruing to any party, upon any breach, default or noncompliance by another
party under this Agreement shall impair any such right, power, or remedy, nor shall it be construed to be a waiver of any such breach,
default or noncompliance, or any acquiescence therein, or of any similar breach, default or noncompliance thereafter occurring. It is
further agreed that any waiver, permit, consent, or approval of any kind or character on any party’s part of any breach, default
or noncompliance under the Agreement or any waiver on such party’s part of any provisions or conditions of this Agreement must be
in writing and shall be effective only to the extent specifically set forth in such writing. All remedies, either under this Agreement,
by law, or otherwise afforded to any party, shall be cumulative and not alternative.

 

3.7 Notices. All notices required or permitted
hereunder shall be in writing and shall be deemed effectively given: (a) upon personal delivery to the party to be notified, (b) when
sent by confirmed electronic mail or facsimile if sent during normal business hours of the recipient; if not, then on the next business
day, (c) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one (1)
day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt.
All communications shall be sent to the party to be notified at the address as set forth on the signature pages hereof or Exhibit A
hereto or at such other address or electronic mail address as such party may designate by ten (10) days advance written notice to the
other parties hereto.

 

3.8 Attorneys’ Fees. In the event
that any suit or action is instituted under or in relation to this Agreement, including without limitation to enforce any provision in
this Agreement, the prevailing party in such dispute shall be entitled to recover from the losing party all fees, costs and expenses of
enforcing any right of such prevailing party under or with respect to this Agreement, including without limitation, such reasonable fees
and expenses of attorneys and accountants, which shall include, without limitation, all fees, costs and expenses of appeals.

 

3.9 Titles and Subtitles. The titles of
the sections and subsections of this Agreement are for convenience of reference only and are not to be considered in construing this Agreement.

 

3.10 Counterparts. This Agreement may be
executed in any number of counterparts, each of which shall be an original, but all of which together shall constitute one instrument.

 

3.11 Aggregation of Shares. All shares
of Registrable Securities held or acquired by affiliated entities or persons or persons or entities under common management or control
shall be aggregated together for the purpose of determining the availability of any rights under this Agreement.

 

3.12 Pronouns. All pronouns contained herein,
and any variations thereof, shall be deemed to refer to the masculine, feminine or neutral, singular or plural, as to the identity of
the parties hereto may require.

 

3.13 Termination. This Agreement shall
terminate and be of no further force or effect upon an Exit (as such term is defined in the Company’s Articles of Association.

 

     

     

    

 

SCHEDULE A

RIGHTS HOLDERS

 

Bill & Melinda Gates Foundation

Andrew Hopkins

Novo Holdings A/S

SVF II Excel (DE) LLC

BlackRock Global Allocation Fund, Inc.

BlackRock Global Funds – Global Allocation Fund

BlackRock Global Allocation V.I. Fund of BlackRock Variable Series Funds, Inc.

BlackRock Global Allocation Portfolio of BlackRock Series Fund, Inc.

BlackRock Global Allocation Fund (Australia)

BlackRock Global Allocation Collective Fund

BlackRock Global Funds – Global Dynamic Equity Fund

BlackRock Capital Allocation Trust

BlackRock Strategic Income Opportunities Portfolio of BlackRock Funds
V

MIC Capital Partners (Ventures) Europe Parallel (Luxembourg) Aggregator,
SCSP

MIC Capital Management 83 RSC LTD.

MW XO Health Innovations Fund, LP

Pivotal bioVenture Partners Fund I, L.P.

NFLS Zeta Limited

Zone III Healthcare Holdings, LLC

Hongkou Capital Master Fund LP

Laurion Capital Master Fund LTD.

Gavin Resources Limited

Data Trophy Limited

Celgene Corporation

Harmony Way Group

Rally Profit Limited

GT Healthcare Partners Fund III, L.P

GT Nextgen Therapies Fund IV, L.P.

Evotech SE

Frontier IP Limited

 

     

     

    

 

IN
WITNESS WHEREOF, the parties hereto have executed this REGISTRATION RIGHTS AGREEMENT
as of the date set forth above.

 

	 	Exscientia plc
	 	 
	 	 
	 	Name: Andrew Hopkins
	 	Title: Chief Executive Officer

 

     

     

    

 

IN WITNESS WHEREOF, the parties hereto
have executed this REGISTRATION RIGHTS AGREEMENT as of the date set forth above.

 
	 	Bill & Melinda Gates
    Foundation

	 	
	 	Name:  	 

	 	Title:  	 

 

     

     

    

 

IN WITNESS WHEREOF, the parties hereto
have executed this REGISTRATION RIGHTS AGREEMENT as of the date set forth above.

 
	 	Andrew Hopkins
	 	 

 

     

     

    

 

IN WITNESS WHEREOF, the parties hereto
have executed this REGISTRATION RIGHTS AGREEMENT as of the date set forth above.

 

	 	Novo Holdings A/S

	 	
	 	Name:  	 Robert Ghenchev

	 	Title:  	 

 

     

     

    

 

IN WITNESS WHEREOF, the parties hereto
have executed this REGISTRATION RIGHTS AGREEMENT as of the date set forth above.

 

	 	SVF
II EXCEL (DE) LLC

	 	
	 	Name:  	 Ian McLean

	 	Title:  	 

 

     

     

    

 

 

IN WITNESS WHEREOF, the parties hereto
have executed this REGISTRATION RIGHTS AGREEMENT as of the date set forth above.

 

	 	BlackRock Global Allocation Fund, Inc.

	 	By:    BlackRock Advisors, LLC, its Investment Advisor

 

	 	 

	 	Name: William Abecassis

	 	Title: Head of Innovation Capital

 

 

	 	BlackRock Global Funds – Global Allocation Fund

	 	By:    BlackRock Investment Management, LLC, as Investment Sub-Advisor

 

	 	 

	 	Name: William Abecassis

	 	Title: Head of Innovation Capital

 

 

	 	BlackRock Global Allocation V.I. Fund of BlackRock Variable Series Funds, Inc.

	 	By:    BlackRock Advisors, LLC, its Investment Advisor

 

	 	 

	 	Name: William Abecassis

	 	Title: Head of Innovation Capital

 

 

	 	BlackRock Global Allocation Portfolio of BlackRock Series Fund, Inc.

	 	By:    BlackRock Advisors, LLC, its Investment Advisor

 

	 	 

	 	Name: William Abecassis

	 	Title: Head of Innovation Capital

 

     

     

    

 

IN WITNESS WHEREOF, the parties hereto
have executed this REGISTRATION RIGHTS AGREEMENT as of the date set forth above.

 

	 	BlackRock Global Allocation Fund (Australia)

	 	By:    BlackRock Investment Management, LLC, as Investment Manager for BlackRock Investment Management (Australia) Limited, the Responsible
Entity of BlackRock Global Allocation Fund (Australia)

 

	 	 

	 	Name: William Abecassis

	 	Title: Head of Innovation Capital

 

 

	 	BlackRock Global Allocation Collective Fund

	 	By:    BlackRock Institutional Trust Company, N.A., not in its individual capacity but as Trustee of the BlackRock Global Allocation Collective
Fund

 

	 	 

	 	Name: William Abecassis

	 	Title: Head of Innovation Capital

 

 

	 	BlackRock Global Funds – Global Dynamic Equity Fund

	 	By:    BlackRock Investment Management, LLC, as Investment Sub-Advisor

 

	 	 

	 	Name: William Abecassis

	 	Title: Head of Innovation Capital

 

 

	 	BlackRock Capital Allocation Trust

	 	By:    BlackRock Advisors, LLC, its Investment Advisor

 

	 	 

	 	Name: William Abecassis

	 	Title: Head of Innovation Capital

 

     

     

    

 

IN WITNESS WHEREOF, the parties hereto
have executed this REGISTRATION RIGHTS AGREEMENT as of the date set forth above.

 

	 	BlackRock Strategic Income Opportunities Portfolio of BlackRock Funds V

	 	By:    BlackRock Advisors, LLC, its Investment Advisor

 

	 	 

	 	Name: William Abecassis

	 	Title: Head of Innovation Capital

 

     

     

    

 

IN WITNESS WHEREOF, the parties hereto
have executed this REGISTRATION RIGHTS AGREEMENT as of the date set forth above.

 

	 	MIC CAPITAL PARTNERS (VENTURES) EUROPE PARALLEL (LUXEMBOURG) AGGREGATOR, SCSP

 

	 	By:    MIC Capital Partners (Ventures) Europe Parallel (Luxembourg) GP S.À.R.L., its unlimited partner (associé commandité)
and manager (gérant)

 

	 	 

	 	Name: Rodney Cannon

	 	Title:	 

 

	 	MIC CAPITAL MANAGEMENT 83 RSC LTD

 

	 	acting by an authorized signatory

 

	 	 

	 	Name: Rodney Cannon

	 	Title:	 

 

     

     

    

 

 

IN WITNESS WHEREOF, the parties hereto
have executed this REGISTRATION RIGHTS AGREEMENT as of the date set forth above.

 

	 	MW XO HEALTH INNOVATIONS FUND, LP

 

	 	By:    Marshall Wace North America, LP, its investment manager

 

	 	By:    Marshall Wace LLC, the general partner of its investment manager
	 	 
	 	 

	 	Name:	 

	 	Title:	 

 

     

     

    

 

IN WITNESS WHEREOF, the parties hereto
have executed this REGISTRATION RIGHTS AGREEMENT as of the date set forth above.

 

	 	Pivotal bioVenture
  Partners Fund I, L.P.

 

	 	By:    Pivotal bioVenture Partners Fund I G.P., L.P. its general partner

 

	 	By: Pivotal bioVenture Partners Fund I U.G.P. Ltd, its general partner, acting by its Managing Partner

 

		
	Name: Robert Hopfner	 

	 	Title: Managing Partner

 

     

     

    

 

 

IN WITNESS WHEREOF, the parties hereto
have executed this REGISTRATION RIGHTS AGREEMENT as of the date set forth above.

 

	 	NFLS ZETA LIMITED
	 	 
	 	acting by a director
	 	 
	 	 
	 	Name: 	     
	 	Title: Director

 

     

     

    

 

IN WITNESS WHEREOF, the parties hereto
have executed this REGISTRATION RIGHTS AGREEMENT as of the date set forth above.

 

	 	Zone
    III Healthcare Holdings, LLC
	 	 
	 	By:
    Farallon Capital Management, LLC, its manager acting by an authorised signatory
	 	 
	 	 
	 	Name:
    Philip Dreyfuss
	 	Title:
    Authorised Signatory

 

     

     

    

 

IN WITNESS WHEREOF, the parties hereto
have executed this REGISTRATION RIGHTS AGREEMENT as of the date set forth above.

 

	 	HONGKOU CAPITAL MASTER
    FUND LP
	 	 
	 	By: Hongkou Capital GP LLC, its general
    partner, acting by its sole member
	 	 
	 	 
	 	Name: Xiaotong Zhou
	 	Title:	        

 

     

     

    

 

IN WITNESS WHEREOF, the parties hereto
have executed this REGISTRATION RIGHTS AGREEMENT as of the date set forth above.

 

	 	LAURION CAPITAL MASTER
    FUND LTD.
	 	 
	 	 
	 	Name: Daniel Woelfel
	 	Title:	       

 

     

     

    

 

IN WITNESS WHEREOF, the parties hereto
have executed this REGISTRATION RIGHTS AGREEMENT as of the date set forth above.

 

	 	GAVIN RESOURCES LIMITED
	 	 
	 	 
	 	Name: 	             
	 	Title:	 

 

     

     

    

 

IN WITNESS WHEREOF, the parties hereto
have executed this REGISTRATION RIGHTS AGREEMENT as of the date set forth above.

 

	 	DATA
    TROPHY LIMITED
	 	 
	 	 
	 	Name: 	         
	 	Title:	 

 

     

     

    

 

 

IN
WITNESS WHEREOF, the parties hereto have executed this REGISTRATION RIGHTS AGREEMENT as of the date set forth above.

 

	 	CELGENE
    CORPORATION
	 	 
	 	 
	 	Name: 	                 
	 	Title:	 

 

     

     

    

 

IN
WITNESS WHEREOF, the parties hereto have executed this REGISTRATION RIGHTS AGREEMENT as of the date set forth above.

 

	 	HARMONY
    WAY GROUP
	 	 
	 	 
	 	Name: 	                 
	 	Title:	 

 

     

     

    

 

IN
WITNESS WHEREOF, the parties hereto have executed this REGISTRATION RIGHTS AGREEMENT as of the date set forth above.

 

	 	RALLY
    PROFIT LIMITED
	 	 
	 	 
	 	Name: 	                 
	 	Title:	 

 

     

     

    

 

IN
WITNESS WHEREOF, the parties hereto have executed this REGISTRATION RIGHTS AGREEMENT as of the date set forth above.

 

	 	GT
    HEALTHCARE PARTNERS FUND III, L.P.
	 	 
	 	 
	 	Name: 	                 
	 	Title:	 

 

	 	GT
    NEXTGEN THERAPIES FUND IV, L.P.
	 	 
	 	 
	 	Name: 	                 
	 	Title:	 

 

     

     

    

 

IN
WITNESS WHEREOF, the parties hereto have executed this REGISTRATION RIGHTS AGREEMENT as of the date set forth above.

 

	 	Evotec
    SE
	 	 
	 	 
	 	Name: 	Enno
    Spillner
	 	Title:	 

 

     

     

    

 

IN
WITNESS WHEREOF, the parties hereto have executed this REGISTRATION RIGHTS AGREEMENT as of the date set forth above.

 

	 	Frontier
    IP Limited
	 	 
	 	 
	 	Name: 	Neil
    Crabb
	 	Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00333-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00333-of-00352.parquet"}]]